🏷

Classifications

Harrison's Part

Mechanistic Nosology

ICIMD (Inherited Metabolic Disorders)

👪

Inheritance

1

Autosomal recessive HP:0000007

Disease requires biallelic (homozygous or compound heterozygous) pathogenic MTO1 variants. In the 35-patient cohort, 17 patients were homozygous and 18 compound heterozygous; carrier parents were unaffected and 12/35 patients were the offspring of consanguineous unions. Notably no patient carried two truncating alleles, indicating that residual MTO1 function is required for viability.

Autosomal recessive inheritance

Show evidence (3 references)

PMID:29331171 SUPPORT Human Clinical

"Sanger sequencing confirmed segregation with disease according to the recessive inheritance model, with carrier status in each parent."

Segregation analysis in the index family confirms autosomal recessive inheritance with unaffected heterozygous parents.

PMID:29331171 SUPPORT Human Clinical

"Of the 35 patients, 17 are homozygous and 13 compound heterozygous for missense variants, four are compound heterozygous for a missense and a frameshift variant and one is compound heterozygous for a missense and a predicted splice-site variant"

Documents the biallelic genotype in every patient of the largest published series.

PMID:22608499 SUPPORT Human Clinical

"A third unrelated individual was homozygous for the latter change."

Homozygosity in an unrelated patient, alongside biparental transmission of two different alleles in the index siblings, establishes recessive inheritance.

◈

Mechanistic Hypotheses

1

Residual MTO1 activity determines survival and severity

mto1_residual_function_dose EMERGING

Evidence balance 2 support

The observation that no patient in 35 carries two truncating alleles, and that the four patients compound heterozygous for p.Ala428Thr plus a frameshift had the earliest presentation (mean 0.04 years) and shortest survival (mean 0.24 years), suggests a dose-response relationship in which residual MTO1 enzymatic activity sets both viability and severity. The hypothesis is consistent with the observation that patients homozygous for p.Thr411Ile tend to be more severe while those homozygous for p.Arg464Cys survive longer, but it is confounded by the wide phenotypic variability among patients sharing an identical genotype, which implies substantial modification by other factors.

Show evidence (2 references)

PMID:29331171 SUPPORT Human Clinical

"We observed that the four patients from three unrelated families who are compound heterozygous for the p.(Ala428Thr) variant and a frameshift variant appear to have more severe presentation: earlier than average age of presentation of clinical features at 0.04 years and shorter than average..."

The primary observation motivating the residual-activity dose hypothesis.

PMID:23929671 SUPPORT In Vitro

"The severity of the yeast respiratory phenotypes partly correlated with the different clinical presentations observed in MTO1 mutant patients, although the clinical outcome was highly variable in patients with the same mutation"

Yeast allele severity partly tracks clinical severity, supporting the hypothesis, but the same sentence records the variability among identical genotypes that limits it.

?

Discussions and Knowledge Gaps

3

Does the anaesthesia-provoked arrhythmia worsening seen in Mto1-deficient mice occur in patients with MTO1 deficiency, and should it change peri-operative management?

HUMAN MODEL MISMATCH OPEN mismatch_anaesthesia_arrhythmia_mouse_only

Attached to

pathophysiology#Cardiac Conduction Instability

The Mto1 gene-trap mouse showed a marked worsening of arrhythmias during induction of and reversal from anaesthesia, and the authors explicitly framed this as a potentially fatal translational risk. No human case series has assessed peri-anaesthetic arrhythmia risk in MTO1 deficiency. Human conduction abnormalities are documented (two patients with Wolff-Parkinson-White, one with tachycardia, and two index siblings who died of sudden bradycardia), so a shared susceptibility is plausible, but the specific anaesthetic trigger is unverified in humans. The mismatch matters because these patients frequently undergo anaesthesia for muscle biopsy, gastrostomy and cardiac procedures.

Proposed experiments

Retrospective multicentre peri-anaesthetic arrhythmia audit

mto1_perianaesthetic_audit

Retrospective multicentre audit of peri-anaesthetic ECG and haemodynamic events in molecularly confirmed MTO1-deficient patients undergoing general anaesthesia, compared with age-matched mitochondrial disease controls.

Prospective peri-anaesthetic Holter monitoring

mto1_prospective_holter

Prospective Holter monitoring around planned anaesthesia in a registry cohort, to quantify arrhythmia burden before, during and after induction and emergence.

Show evidence (1 reference)

PMID:25506927 SUPPORT Model Organism

"A translational consequence of this mouse model may be to caution against anaesthesia-related cardiac arrhythmias which may be fatal in patients."

The mouse observation whose human validity is the open question.

Why is the neurological phenotype nearly universal in patients but largely absent in the Mto1-deficient mouse?

HUMAN MODEL MISMATCH OPEN mismatch_neurological_phenotype_absent_in_mouse

Attached to

pathophysiology#Neuronal and Retinal Ganglion Cell Energy Failure

Global developmental delay or intellectual disability affects 97% of MTO1-deficient patients, and structural brain abnormalities are seen in 70% of those imaged. Yet neurological examination was largely normal in the Mto1-deficient mouse, whose phenotype was dominated by cardiovascular disease. The discrepancy limits the mouse as a preclinical model for the neurological arm of the disease - which is the arm most in need of therapy in long-term survivors - and raises the question of whether it reflects the hypomorphic nature of the gene-trap allele, species differences in neuronal dependence on tau-m5U-modified tRNAs, or the shorter murine lifespan.

Proposed experiments

Deep neurobehavioural phenotyping of aged and allelic-series Mto1 mice

mto1_aged_mouse_neurophenotyping

Deep neurobehavioural and neuropathological phenotyping of aged Mto1-deficient mice, and of allelic series recapitulating the severe human genotypes (e.g. missense plus null), to test whether a neurological phenotype emerges at lower residual activity or later ages.

Cross-species tissue survey of tau-m5U occupancy

mto1_cross_species_taum5u_occupancy

Quantify tau-m5U occupancy tissue-by-tissue in mouse versus human brain, heart and muscle to test whether the neuronal requirement for the modification differs between species.

Show evidence (2 references)

PMID:25506927 SUPPORT Model Organism

"In contrast, neurological examination was largely normal in Mto1-deficient mice."

Documents the absence of the neurological phenotype in the mouse model.

PMID:29331171 SUPPORT Human Clinical

"global developmental delay/intellectual disability present in 28/29 (97%)"

Documents the near-universal human neurological phenotype that the mouse fails to reproduce.

What determines the marked phenotypic variability between patients carrying identical MTO1 genotypes, including within families?

KNOWLEDGE GAP OPEN gap_genotype_phenotype_variability_modifiers

Attached to

pathophysiology#Loss of MTO1 Wobble Uridine Taurinomethylation of Mitochondrial tRNAs

Patients homozygous for the same MTO1 allele range from neonatal death to survival into the third decade with normal scholastic performance, and cardiomyopathy - the eponymous feature - is absent in a sixth of patients. Candidate modifiers include mtDNA haplogroup or co-occurring mt-tRNA variants (one family carried a homoplasmic MT-TF m.593T>G variant proposed to act synergistically), taurine availability (taurine is a substrate for the MTO1 reaction and taurine starvation reduces tau-m5U frequency in cultured cells and animal tissues), and timing of metabolic treatment. None has been tested systematically. Resolving this is a prerequisite for prognostic counselling and for interpreting any future trial.

Proposed experiments

Genotype-stratified registry with mtDNA background analysis

mto1_registry_mtdna_background

Genotype-stratified natural history registry with mtDNA haplogroup and full mtDNA sequencing, to test whether mitochondrial background predicts severity among patients sharing a nuclear MTO1 genotype.

Taurine availability as a modifier of tau-m5U occupancy

mto1_taurine_modifier_test

Measure plasma and tissue taurine and tau-m5U occupancy in patient-derived cells across the severity spectrum, and test whether taurine supplementation increases tau-m5U occupancy and mitochondrial translation in hypomorphic MTO1 patient cells.

Show evidence (2 references)

PMID:34990597 SUPPORT Human Clinical

"Of note, patients with the same genetic mutation may not have the same clinical presentation. Additional MTO1 defificiency cases will help to make genotype-phenotype correlations clearer."

States the unexplained genotype-phenotype discordance that defines this gap.

PMID:29390138 SUPPORT In Vitro

"Taurine starvation resulted in downregulation of τm5U frequency in cultured cells and animal tissues (cat liver and flatfish)."

Establishes taurine availability as a modifiable determinant of tau-m5U occupancy, making it a concrete candidate modifier worth testing in patients.

⚙

Pathophysiology

8

Loss of MTO1 Wobble Uridine Taurinomethylation of Mitochondrial tRNAs

MTO1 and its GTPase partner GTPBP3 jointly catalyse installation of 5-taurinomethyluridine (tau-m5U) at the anticodon first (wobble) position, U34, of five mitochondrially encoded tRNAs: those for glutamine, glutamate, lysine, leucine(UUR) and tryptophan. The reaction consumes taurine and 5,10-methylene-tetrahydrofolate as substrates; older literature describes the homologous bacterial/yeast product as 5-carboxymethylaminomethyluridine (cmnm5U), the glycine-substituted counterpart that appears in human cells when taurine is depleted. Biallelic MTO1 missense or truncating variants reduce or abolish the enzyme's modifying activity. No reported patient carries two truncating alleles, indicating that some residual MTO1 activity is required for human viability; this is the molecular origin of the whole disease cascade.

MTO1 hgnc:19261

mitochondrial tRNA wobble uridine modification GO:0070899 ↓ DECREASED

mitochondrial matrix GO:0005759

Downstream

Impaired Mitochondrial Translation Hypomodified wobble uridines destabilise codon-anticodon pairing and reduce the accuracy and efficiency of mtDNA-encoded protein synthesis.

Show evidence (5 references)

PMID:29390138 SUPPORT In Vitro

"we elucidated τm5U biogenesis by confirming that 5,10-methylene-tetrahydrofolate and taurine are metabolic substrates for τm5U formation catalyzed by MTO1 and GTPBP3."

Directly establishes that MTO1 (with GTPBP3) catalyses tau-m5U formation and identifies the two metabolic substrates.

PMID:29390138 SUPPORT In Vitro

"Modified uridine containing taurine, 5-taurinomethyluridine (τm5U), is found at the anticodon first position of mitochondrial (mt-)transfer RNAs (tRNAs)."

Locates the modification at the wobble position of mitochondrial tRNAs.

PMID:33836087 SUPPORT Human Clinical

"pathogenic variants in MTO1 for the biosynthesis of τm5U of tRNAGlu, tRNAGln, tRNALys, tRNATrp and tRNALeu(UUR) were associated with hypertrophic cardiomyopathy (HCM)"

Enumerates the five mitochondrial tRNA substrates of MTO1 and links their hypomodification to the cardiac phenotype.

+ 2 more references

Impaired Mitochondrial Translation

The tau-m5U/cmnm5U wobble modification increases the accuracy and efficiency of mtDNA translation by stabilising tRNA structure, ribosome binding and correct codon-anticodon pairing. When it is lost, synthesis of the 13 mtDNA-encoded polypeptides is attenuated. In the mto1 knock-out zebrafish the mechanism is broader than decoding alone: the mutant tRNAs show altered conformation, increased nuclease sensitivity and globally reduced aminoacylation, and MTO1 additionally interacts with the mitochondrial poly(A) polymerase MTPAP so that its loss alters polyadenylation of cox1, cox3 and nd1 mRNAs. The translation defect was demonstrated directly in a recombinant yeast model carrying the patient alleles.

mitochondrial translation GO:0032543 ↓ DECREASED

Downstream

Combined Respiratory Chain Complex Deficiency Reduced synthesis of the mtDNA-encoded core subunits leaves complexes I, III, IV and V under-assembled; complex II, which is entirely nuclear-encoded, is spared.

Show evidence (5 references)

PMID:22608499 SUPPORT In Vitro

"In both humans and yeast, MTO1 increases the accuracy and efficiency of mtDNA translation by catalyzing the 5-carboxymethylaminomethylation of the wobble uridine base in three mitochondrial tRNAs (mt-tRNAs)."

States the functional role of the modification in translational accuracy and efficiency.

PMID:22608499 SUPPORT In Vitro

"Lastly, in vivo mtDNA translation was impaired in the mutant yeast strains."

Direct experimental demonstration that patient-equivalent MTO1 alleles impair mtDNA translation.

PMID:33836087 SUPPORT Model Organism

"Notably, mto1KO zebrafish exhibited the global decreases in the aminoacylation of mitochondrial tRNAs with the taurine modification."

Shows in vivo that loss of the taurine modification reduces mitochondrial tRNA aminoacylation, an additional route to translational failure.

+ 2 more references

Combined Respiratory Chain Complex Deficiency

Attenuated mitochondrial translation produces a combined, rather than isolated, respiratory chain enzyme deficiency, because the 13 mtDNA-encoded proteins are distributed across complexes I (seven subunits), III (one), IV (three) and V (two), while complex II is entirely nuclear-encoded and unaffected. In patient skeletal muscle the most frequent pattern is a combined complex I and complex IV deficiency; complex IV was deficient in 28/30 muscle biopsies and a combined deficiency was present in 27/30. Fibroblasts are an unreliable tissue for this assay - respiratory chain enzymes were normal in 4/10 patient fibroblast lines - so a normal fibroblast result does not exclude the diagnosis.

oxidative phosphorylation GO:0006119 ↓ DECREASED

mitochondrial respiratory chain complex I GO:0045271 mitochondrial respiratory chain complex IV GO:0045277

skeletal muscle tissue UBERON:0001134

Downstream

Cellular Energy Deficit and Lactate Overproduction Impaired electron transport limits ATP output and diverts pyruvate to lactate.

Cardiomyocyte Bioenergetic Failure and Hypertrophic Remodeling Cardiomyocytes, with the highest oxidative demand of any cell type in the body, are the first tissue to decompensate.

Neuronal and Retinal Ganglion Cell Energy Failure Neurons and retinal ganglion cells are the second major high-oxidative-demand target of the respiratory chain defect.

Metabolic Reprogramming via the HIF-PPARgamma-UCP2-AMPK Axis MTO1-deficient cells mount a distinctive compensatory transcriptional and metabolic response to the OXPHOS defect.

Show evidence (4 references)

PMID:29331171 SUPPORT Human Clinical

"Respiratory chain enzyme (RCE) analysis in muscle was performed in 30 patients. Complex IV was deficient in 28/30 cases and 27/30 cases showed evidence of combined deficiency."

Quantifies the combined respiratory chain deficiency in patient muscle across the cohort.

PMID:29331171 SUPPORT Human Clinical

"This may be explained by the destination of the 13 mtDNA encoded proteins; seven are core subunits of complex I, three of complex IV, two of complex V (although this OXPHOS component cannot be easily measured in frozen diagnostic muscle samples) and one of complex III; complex II is entirely..."

Explains mechanistically why a translation defect yields a combined, complex-II-sparing enzyme deficiency.

PMID:22608499 SUPPORT Human Clinical

"Accordingly, mutant muscle and fibroblasts showed variably combined reduction in mtDNA-dependent respiratory chain activities."

The index report already established the variably combined respiratory chain reduction in patient tissue.

+ 1 more reference

Cellular Energy Deficit and Lactate Overproduction

With oxidative phosphorylation constrained, cells shift to glycolysis and reduce accumulating pyruvate to lactate, producing the lactic acidosis that is the single most consistent biochemical feature of the disorder (eventually present in 35/35 patients, with peak plasma lactate averaging 13.6 mmol/L and reaching 57.8 mmol/L). Pyruvate accumulation also drives transamination to alanine, producing the characteristic hyperalaninemia, and a broad panel of mitochondrial markers - ketones, TCA-cycle intermediates, tyrosine metabolites, dicarboxylic acids and 3-methylglutaconate - appears in urine.

lactate biosynthetic process GO:0019249 ↑ INCREASED

Show evidence (2 references)

PMID:29331171 SUPPORT Human Clinical

"An extensive review of all known MTO1 deficiency cases revealed the most common features at presentation to be lactic acidosis (LA) (21/34; 62% cases) and hypertrophic cardiomyopathy (15/34; 44% cases). Eventually lactic acidosis and hypertrophic cardiomyopathy are described in 35/35 (100%) and..."

Establishes lactic acidosis as the most frequent presenting biochemical feature and as universal in the cohort once measured.

PMID:29331171 SUPPORT Human Clinical

"An elevated plasma alanine was documented in 21/24"

Quantifies hyperalaninemia as the second consistent biochemical consequence of pyruvate accumulation.

Metabolic Reprogramming via the HIF-PPARgamma-UCP2-AMPK Axis

Patient fibroblasts and MTO1-silenced cells show a specific compensatory reprogramming: AMPK is inactivated, UCP2 and PPARgamma are downregulated, and HIF-1 is activated. Glycolysis and oxidative phosphorylation become uncoupled and fatty-acid metabolism is altered, with accumulation of lipid droplets in MTO1 fibroblasts. Notably this response is the mirror image of that seen in GTPBP3-depleted cells - which activate AMPK, raise UCP2/PPARgamma and inactivate HIF-1 - even though the two proteins act on the same modification, suggesting one of them has an additional, non-tRNA-modifying role. This node is curated as PROVISIONAL because it rests on fibroblast and knockdown data from a single group and has not been demonstrated in patient heart or muscle.

fibroblast CL:0000057

Show evidence (3 references)

PMID:29348686 SUPPORT In Vitro

"Using fibroblasts from an MTO1 patient and MTO1 silenced cells, we found that the MTO1 deficiency is associated with a metabolic reprogramming mediated by inactivation of AMPK, down regulation of the uncoupling protein 2 (UCP2) and transcription factor PPARγ, and activation of the hypoxia..."

Defines the direction of each arm of the reprogramming axis in MTO1-deficient cells.

PMID:29348686 SUPPORT In Vitro

"As a result, glycolysis and oxidative phosphorylation are uncoupled, while fatty acid metabolism is altered, leading to accumulation of lipid droplets in MTO1 fibroblasts."

Documents the downstream metabolic consequence, including lipid droplet accumulation.

PMID:29348686 SUPPORT In Vitro

"Therefore, the HIF-PPARγ-UCP2-AMPK axis is operating differently in MTO1- and GTPBP3-defective cells, which strongly suggests that one of these proteins has an additional role, besides mitochondrial-tRNA modification."

Supports the claim only partially - the divergence between MTO1 and GTPBP3 is observed, but which protein carries the extra function, and whether the axis operates the same way in heart or muscle, remains unresolved.

Cardiomyocyte Bioenergetic Failure and Hypertrophic Remodeling

Cardiomyocytes have an extremely high and continuous ATP requirement, so they are the tissue most sensitive to a combined respiratory chain defect; infantile hypertrophic cardiomyopathy is a key clinical feature across many mitochondrial disorders and is the presenting feature of MTO1 deficiency in almost half of patients. In the Mto1 gene-trap mouse the myocardial damage was attributed specifically to complex I deficiency and mitochondrial dysfunction, and in the mto1 knock-out zebrafish the ablation produced heart developmental defects, cardiomyocyte hypertrophy and myocardial fibre disarray in the ventricles, recapitulating the human histological picture.

cardiac muscle cell CL:0000746

heart UBERON:0000948

Downstream

Cardiac Conduction Instability Mitochondrial dysfunction in the conduction system and working myocardium predisposes to bradyarrhythmia and pre-excitation, most clearly documented in the mouse model.

Show evidence (4 references)

PMID:23929671 SUPPORT Other

"Cardiomyocytes, with their extremely high request of energy, are one of the major targets of OXPHOS impairment, and infantile hypertrophic cardiomyopathy is a key clinical feature in many mitochondrial disorders."

States the bioenergetic rationale for cardiac vulnerability. Tagged OTHER because the sentence is background framing rather than a patient or experimental observation.

PMID:33836087 SUPPORT Model Organism

"These mitochondria dysfunctions caused heart development defects and hypertrophy of cardiomyocytes and myocardial fiber disarray in ventricles."

Demonstrates in vivo that Mto1 loss is sufficient to produce cardiomyocyte hypertrophy and myofibre disarray.

PMID:33836087 SUPPORT Model Organism

"These cardiac defects in the mto1KO zebrafish recapitulated the clinical phenotypes in HCM patients carrying the MTO1 mutation(s)."

The authors' explicit statement that the animal cardiac phenotype recapitulates the human one.

+ 1 more reference

Cardiac Conduction Instability

Beyond structural hypertrophy, MTO1 deficiency destabilises cardiac rhythm. The MTO1-deficient mouse showed bradycardia alongside cardiomyopathy and, of direct translational relevance, a marked worsening of arrhythmias during induction of and recovery from anaesthesia - prompting the authors to caution against anaesthesia-related arrhythmia in patients. In humans, two patients in the reference cohort had Wolff-Parkinson-White pre-excitation, one had tachycardia, and the two index siblings of the original 2012 report died in the first days of life of sudden bradycardia. The peri-anaesthetic risk itself is supported only by mouse data and is therefore curated as PROVISIONAL with an accompanying HUMAN_MODEL_MISMATCH discussion.

heart UBERON:0000948

Show evidence (3 references)

PMID:25506927 SUPPORT Model Organism

"As in patients, the most prominent signs and symptoms were cardiovascular and included bradycardia and cardiomyopathy. In addition, the mutant mice showed a marked worsening of arrhythmias during induction and reversal of anaesthesia."

Documents both baseline bradycardia and the anaesthesia-provoked arrhythmia worsening in the mouse model.

PMID:25506927 SUPPORT Model Organism

"A translational consequence of this mouse model may be to caution against anaesthesia-related cardiac arrhythmias which may be fatal in patients."

The peri-anaesthetic caution is explicitly framed by the authors as a hypothesised translational consequence of a mouse finding, not a demonstrated human risk, so this supports the claim only partially.

PMID:23929671 SUPPORT Human Clinical

"who died in their first days of life due to sudden bradycardia"

Human evidence that fatal bradyarrhythmia occurs in MTO1 deficiency, in the two index siblings of the original report.

Neuronal and Retinal Ganglion Cell Energy Failure

Neurons and retinal ganglion cells, like cardiomyocytes, are high-oxidative-demand, poorly regenerating cell types, and they constitute the second major target of the translation defect. Clinically this produces the near-universal global developmental delay/intellectual disability, plus hypotonia, seizures, ataxia and optic atrophy; imaging shows basal ganglia, cerebellar peduncle and corpus callosum abnormalities in most patients scanned. Optic neuropathy is prominent enough in some families that the acronym ONCE (Optic Neuropathy, Cardiomyopathy and Encephalopathy with lactic acidosis and combined oxidative phosphorylation deficiency) was coined for the homozygous p.Arg504Cys presentation.

neuron CL:0000540 retinal ganglion cell CL:0000740

Show evidence (3 references)

PMID:29331171 SUPPORT Human Clinical

"cases included lesions of the basal ganglia and cerebellar peduncles and hypoplasia of the corpus callosum"

Documents the structural CNS consequences of the energy deficit in the patients imaged.

PMID:27256614 SUPPORT Human Clinical

"We report clinical and biochemical finding from three unrelated patients presenting ONCE (Optic Neuropathy, Cardiomyopathy and Encephalopathy with lactic acidosis and combined oxidative phosphorylation deficiency) syndrome."

Establishes the optic-neuropathy-plus-encephalopathy presentation as a recognised MTO1 phenotype.

PMID:26061759 SUPPORT Human Clinical

"Thus, in patients with a moderate clinical presentation due to MTO1 mutations, the presence of an optic atrophy should be considered."

Confirms optic atrophy as a recognised feature that should be looked for in milder MTO1 presentations.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

19

Cardiovascular 2

Hypertrophic Cardiomyopathy FREQUENT HP:0001639

Show evidence (2 references)

PMID:29331171 SUPPORT Human Clinical

"An extensive review of all known MTO1 deficiency cases revealed the most common features at presentation to be lactic acidosis (LA) (21/34; 62% cases) and hypertrophic cardiomyopathy (15/34; 44% cases). Eventually lactic acidosis and hypertrophic cardiomyopathy are described in 35/35 (100%) and..."

Direct quantitative support; the eventual 27/34 (79%) sits at the top of the FREQUENT (30-79%) band.

PMID:29331171 SUPPORT Human Clinical

"Together, these six cases prove that HCM is not a hallmark clinical feature of this condition; in fact it was only reported as a presenting feature in approximately half of cases"

Qualifies the association: cardiomyopathy is common but not obligatory, which is why the frequency is FREQUENT rather than VERY_FREQUENT despite the disease name.

Wolff-Parkinson-White Syndrome OCCASIONAL HP:0001716

Show evidence (1 reference)

PMID:29331171 SUPPORT Human Clinical

"21FPakistanC0.42 yrLA, HCM, WPW; DD12 yrYYYYNNRNrHCMWPWPericardial effusionNRNR"

Patient 21's Table 1 row directly records WPW; patient 5 also carries the WPW annotation in the table's Abnormal Rhythm column. The OCCASIONAL band is a count derived from that table (2/35), not a summary statistic reported by the authors.

Digestive 1

Feeding Difficulties FREQUENT HP:0011968

Show evidence (1 reference)

PMID:29331171 SUPPORT Human Clinical

"with global developmental delay/intellectual disability present in 28/29 (97%), feeding difficulties in 17/35 (49%), failure to thrive in 12/35 (34%), seizures in 12/35 (34%), optic atrophy in 11/21 (52%) and ataxia in 7/34 (21%)"

Direct quantitative support; 17/35 (49%) falls in the FREQUENT (30-79%) band.

Eye 1

Optic Atrophy FREQUENT HP:0000648

Show evidence (3 references)

PMID:29331171 SUPPORT Human Clinical

"with global developmental delay/intellectual disability present in 28/29 (97%), feeding difficulties in 17/35 (49%), failure to thrive in 12/35 (34%), seizures in 12/35 (34%), optic atrophy in 11/21 (52%) and ataxia in 7/34 (21%)"

Direct quantitative support; 11/21 (52%) falls in the FREQUENT (30-79%) band.

PMID:29331171 SUPPORT Human Clinical

"cases with thinning of the retinal nerve fibre layer documented in three of these cases"

Documents structural retinal nerve fibre layer thinning accompanying the optic atrophy.

PMID:26061759 SUPPORT Human Clinical

"Ophthalmic investigations (slit lamp examination, funduscopy, OCT scan of the optic nerve, ERG and VEP) disclosed mild or no decreased visual acuity, but pale optic disc, loss of temporal optic fibers and decreased VEPs."

Characterises the optic neuropathy phenotype in detail, including preserved acuity despite objective optic nerve findings.

Metabolism 1

Lactic Acidosis VERY_FREQUENT HP:0003128

Show evidence (2 references)

PMID:29331171 SUPPORT Human Clinical

"Eventually lactic acidosis and hypertrophic cardiomyopathy are described in 35/35 (100%) and 27/34 (79%) of patients with MTO1 deficiency, respectively"

Direct quantitative support for both the association and the frequency band. VERY_FREQUENT rather than OBLIGATE is used because the denominator reflects only patients in whom lactate was measured and the authors flag ascertainment bias toward lactic acidosis.

PMID:22608499 SUPPORT Human Clinical

"Mutations of the mitochondrial-tRNA modifier MTO1 cause hypertrophic cardiomyopathy and lactic acidosis."

The index report names lactic acidosis as one of the two defining features of the disorder.

Musculoskeletal 2

Hypotonia FREQUENT HP:0001252

Show evidence (2 references)

PMID:29331171 SUPPORT Human Clinical

"but it eventually occurred in 22/35"

Direct quantitative support for the frequency band. The quoted clause is the eventual-hypotonia count from the sentence "Hypotonia was identified in 10/35 ... cases at presentation but it eventually occurred in 22/35 ... cases"; 22/35 is 63%, in the FREQUENT (30-79%) band. Only the bracket-free clause is quoted because the source sentence interleaves square-bracketed confidence intervals.

PMID:29331171 SUPPORT Human Clinical

"Other commonly occurring clinical features identified were feeding difficulties, FTT, hypotonia and ocular pathology."

Supports the disease-phenotype association itself, independently of the frequency band.

Muscle Weakness HP:0001324

Show evidence (2 references)

PMID:29331171 SUPPORT Human Clinical

"The most frequent neurologic features of primary mitochondrial disease are muscle weakness with hypotonia, followed by clinical or imaging features of central neurological disease and cognitive impairment/decline"

Provides disease-class context rather than MTO1-specific support, so this item is PARTIAL. No frequency band is asserted because the cohort does not report a summary denominator for weakness.

PMID:29331171 SUPPORT Human Clinical

"decreased muscle mass and proximal muscle strength"

Directly documents reduced proximal muscle strength in an MTO1-deficient patient.

Nervous System 6

Global Developmental Delay and Intellectual Disability VERY_FREQUENT HP:0001263

Show evidence (1 reference)

PMID:29331171 SUPPORT Human Clinical

"with global developmental delay/intellectual disability present in 28/29 (97%), feeding difficulties in 17/35 (49%), failure to thrive in 12/35 (34%), seizures in 12/35 (34%), optic atrophy in 11/21 (52%) and ataxia in 7/34 (21%)"

Direct quantitative support for the 28/29 (97%) frequency, placing it in the VERY_FREQUENT (80-99%) band.

Intellectual Disability HP:0001249

Show evidence (1 reference)

PMID:29331171 SUPPORT Human Clinical

"Virtually all of the patients for whom clinical information was available at a later age did show an intellectual developmental disorder and/or other neurologic impairment."

Supports the association in survivors. No frequency band is asserted separately from Global Developmental Delay because the cohort reports the two features under a combined GDD/ID denominator.

Seizures FREQUENT HP:0001250

Show evidence (1 reference)

PMID:29331171 SUPPORT Human Clinical

"with global developmental delay/intellectual disability present in 28/29 (97%), feeding difficulties in 17/35 (49%), failure to thrive in 12/35 (34%), seizures in 12/35 (34%), optic atrophy in 11/21 (52%) and ataxia in 7/34 (21%)"

Direct quantitative support; the eventual 12/35 (34%) falls at the lower edge of the FREQUENT band.

Ataxia OCCASIONAL HP:0001251

Show evidence (1 reference)

PMID:29331171 SUPPORT Human Clinical

"with global developmental delay/intellectual disability present in 28/29 (97%), feeding difficulties in 17/35 (49%), failure to thrive in 12/35 (34%), seizures in 12/35 (34%), optic atrophy in 11/21 (52%) and ataxia in 7/34 (21%)"

Direct quantitative support; the eventual 7/34 (21%) falls in the OCCASIONAL (5-29%) band.

Abnormal Basal Ganglia Morphology HP:0002134

Show evidence (1 reference)

PMID:29331171 SUPPORT Human Clinical

"cases included lesions of the basal ganglia and cerebellar peduncles and hypoplasia of the corpus callosum"

Supports basal ganglia involvement. No frequency band is asserted for this HPO term specifically because the reported 14/20 denominator covers any brain MRI abnormality, not basal ganglia lesions alone.

Hypoplasia of the Corpus Callosum HP:0002079

Show evidence (1 reference)

PMID:29331171 SUPPORT Human Clinical

"cases included lesions of the basal ganglia and cerebellar peduncles and hypoplasia of the corpus callosum"

Names corpus callosum hypoplasia among the documented MRI abnormalities. No frequency is asserted because the cohort does not report a separate denominator for this finding.

Growth 1

Failure to Thrive FREQUENT HP:0001508

Show evidence (1 reference)

PMID:29331171 SUPPORT Human Clinical

"with global developmental delay/intellectual disability present in 28/29 (97%), feeding difficulties in 17/35 (49%), failure to thrive in 12/35 (34%), seizures in 12/35 (34%), optic atrophy in 11/21 (52%) and ataxia in 7/34 (21%)"

Direct quantitative support; 12/35 (34%) falls at the lower edge of the FREQUENT (30-79%) band.

Other 5

Hepatic Dysfunction OCCASIONAL Abnormal liver physiology HP:0031865

Show evidence (2 references)

PMID:29331171 SUPPORT Human Clinical

"Hepatic dysfunction was infrequent, present in 3/35"

Direct quantitative support; 3/35 is 9%, in the OCCASIONAL (5-29%) band.

PMID:29331171 SUPPORT Human Clinical

"While TRMU mutations may result in severe infantile hepatopathy or renal failure neither hepatopathy nor renal pathology are common features in MTO1 deficiency"

Contrasts the low hepatic burden of MTO1 deficiency with the hepatopathy characteristic of the mechanistically adjacent TRMU deficiency.

Hyperalaninemia VERY_FREQUENT HP:0003348

Show evidence (1 reference)

PMID:29331171 SUPPORT Human Clinical

"An elevated plasma alanine was documented in 21/24"

Direct quantitative support; 21/24 is 88%, in the VERY_FREQUENT (80-99%) band.

Increased CSF Lactate HP:0002490

Show evidence (1 reference)

PMID:29331171 SUPPORT Human Clinical

"CSF lactate was elevated in 5/6 cases"

Supports the association. No frequency band is asserted despite the nominal 83% because the denominator is only six patients and the confidence interval reported by the authors spans three FrequencyEnum bands.

Decreased Activity of Mitochondrial Complex IV VERY_FREQUENT HP:0008347

Show evidence (1 reference)

PMID:29331171 SUPPORT Human Clinical

"Complex IV was deficient in 28/30 cases and 27/30 cases showed evidence of combined deficiency."

Direct quantitative support; 28/30 (93%) falls in the VERY_FREQUENT (80-99%) band among biopsied patients.

Decreased Activity of Mitochondrial Complex I FREQUENT HP:0011923

Show evidence (1 reference)

PMID:29331171 SUPPORT Human Clinical

"Of the combined deficiencies, complex I and IV deficiency were most commonly seen (20/30 cases) while combined complex I, III and IV deficiency, was present in 6/30 cases."

Direct quantitative support; complex I deficiency appears in 20/30 (I+IV) plus 6/30 (I+III+IV) of biopsied patients, placing it in the FREQUENT (30-79%) band.

🧬

Genetic Associations

2

MTO1

Gene: MTO1 hgnc:19261 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (5 references)

PMID:22608499 SUPPORT Human Clinical

"we used next-generation exome sequencing to identify mutations in MTO1, which encodes mitochondrial translation optimization 1."

Original gene discovery establishing MTO1 as the causal gene.

PMID:29331171 SUPPORT Human Clinical

"In the 35 patients from 26 unrelated families, we identified 19 different MTO1 (NM 012123.3; NP 036255) variants (7 published and 12 unpublished): 15 missense, 3 frameshifts and one splice-site"

Defines the allelic spectrum across the largest published cohort.

PMID:29331171 SUPPORT Human Clinical

"The missense variants affect the conserved amino acids located in the: FAD-binding domain (n = 1), insertion domain 2 (n = 1), GidA specific sequence motif (n = 5) and central helical domain (n = 8) of the MTO1"

Localises the pathogenic missense variants to four functional protein domains.

+ 2 more references

MT-TF

Gene: MT-TF hgnc:7481 relationship_type: MODIFIER

Show evidence (1 reference)

PMID:26061759 SUPPORT Human Clinical

"The association with the mitochondrial mutation m.593T>G could act synergistically to worsen the complex I deficiency and modulate the MTO1-related disease."

Supports the modifier hypothesis only partially - the authors state the synergy as a possibility ("could act") in a single family, with no functional demonstration of epistasis.

💊

Medical Actions

6

Dichloroacetate

Action: Pharmacotherapy NCIT:C15986

Agent: dichloroacetate CHEBI:28240

Dichloroacetate (DCA) was given to 8/25 treated patients with the intent of lowering lactate. One patient, homozygous for p.Ala428Thr, improved dramatically on permanent DCA plus cofactors and was alive at 20 years with compensated stable hypertrophic cardiomyopathy and normal scholastic performance. The cohort authors caution that DCA is expected to improve lactic acidosis without a clear effect on seizures or neurological outcome, and that the concurrent cardiac improvement in that patient may have been natural disease course rather than drug effect. This is uncontrolled single-patient evidence.

Mechanism Target:

INHIBITS Cellular Energy Deficit and Lactate Overproduction — DCA is used to reduce circulating lactate; it does not address the underlying translation defect.

Show evidence (2 references)

PMID:23929671 SUPPORT Human Clinical

"the clinical outcome was highly variable in patients with the same mutation and seemed also to depend on timely start of pharmacological treatment, centered on the control of lactic acidosis by dichloroacetate."

Supports a possible benefit of early DCA, but only as an inference from variable outcomes in a handful of patients with the same genotype, not from a controlled comparison.

PMID:29331171 SUPPORT Human Clinical

"Whether or not DCA had a direct positive effect on HCM in patient no. 16 is uncertain and the improvement may have been part of the natural disease course in this case."

The cohort authors explicitly qualify the single reported DCA success, which is why this treatment is curated with PARTIAL evidence.

Ketogenic diet

Action: Dietary Intervention NCIT:C15447

Trialled in 5/22 patients. Three were deemed unresponsive; one showed clear clinical improvement (normalised lactate, learned to walk, resolution of mild cardiomyopathy) and one had initially better seizure control that later deteriorated. The rationale is strengthened by amelioration of the oxidative-phosphorylation defect on a ketogenic diet in MTO1 knockout mice. The cohort authors conclude the data are insufficient to draw conclusions but that it may be worth cautiously considering in MTO1-deficient patients with seizures.

Show evidence (2 references)

PMID:29331171 SUPPORT Human Clinical

"A ketogenic diet may have exerted a favourable effect on seizures in 2/5 patients."

Documents a possible but inconsistent anticonvulsant benefit in a handful of patients.

PMID:29331171 SUPPORT Human Clinical

"Thus the current data are insufficient to draw conclusions about the effectiveness of the ketogenic diet"

The cohort authors' own assessment of the evidence base, recorded here so the treatment is not overstated.

Mitochondrial cofactor cocktail

Action: Nutritional Support NCIT:C15433

Various combinations of L-carnitine (14/25), coenzyme Q10 (17/25), riboflavin (11/25), vitamin C (6/25), thiamine (5/25) and vitamin E (4/25) were given according to local practice. None had an appreciable effect. Riboflavin in particular was a rational candidate because MTO1 is a FAD-containing enzyme, but it did not improve respiratory chain or fibroblast oxygen consumption measurements. Curated here to document that this widely used empirical regimen has not shown benefit in this disorder.

Show evidence (2 references)

PMID:29331171 REFUTE Human Clinical

"documented objective improvement was rare"

Refutes benefit from the empirical mitochondrial cocktail across the cohort; the same paragraph records that L-carnitine, coenzyme Q10, vitamin C, vitamin E, riboflavin and thiamine "had no appreciable effect".

PMID:29331171 REFUTE Human Clinical

"As MTO1 is a FAD moiety-containing enzyme, riboflavin supplementation was investigated as a possible treatment without observed success in either respiratory chain or fibroblast oxygen consumption analyses"

Specifically refutes the mechanistically motivated riboflavin hypothesis.

N-acetylcysteine

Action: Pharmacotherapy NCIT:C15986

Agent: N-acetyl-L-cysteine CHEBI:28939

An investigational, cell-culture-only lead. N-acetylcysteine (but not L-cysteine) had a beneficial effect on mitochondrial translation in MTO1- and TRMU-deficient patient fibroblasts. The rationale is that cysteine supplies the sulfur for the 2-thiomodification that is coupled to the wobble-uridine modification MTO1 installs. No human trial in MTO1 deficiency has been reported.

Mechanism Target:

RESTORES Impaired Mitochondrial Translation — NAC supplementation partially rescued the mitochondrial translation defect in MTO1-deficient fibroblasts in vitro.

Show evidence (2 references)

PMID:27854233 SUPPORT In Vitro

"In contrast, N-acetyl-cysteine had a beneficial effect on mitochondrial translation in TRMU and MTO1 deficient fibroblasts."

The single direct experimental result supporting NAC in MTO1 deficiency; it is fibroblast data only.

PMID:27854233 SUPPORT In Vitro

"Further studies are needed to explore the full potential of cysteine supplementation as a treatment for patients with mitochondrial disease."

The authors' own statement that the finding is not yet translatable to patient care.

Supportive and multidisciplinary care

Action: Supportive Care NCIT:C15747

In the absence of disease-modifying therapy, management is supportive: inotropes and heart failure management for cardiomyopathy, serial echocardiography (cardiomyopathy develops over time in patients who do not have it at presentation), tube feeding for feeding difficulties and failure to thrive, antiseizure medication, ophthalmological surveillance for optic atrophy, and developmental/rehabilitative support. Peri-anaesthetic cardiac monitoring is prudent given the arrhythmia worsening observed around anaesthesia in the mouse model.

Show evidence (2 references)

PMID:29331171 SUPPORT Human Clinical

"Although subjective clinical improvement was observed in a small number of patients on therapies such as ketogenic diet and dichloroacetate, no evidence-based effective therapy exists."

Establishes that care is necessarily supportive because no disease-modifying therapy has been validated.

PMID:29331171 SUPPORT Human Clinical

"In general, early diagnosis is important for genetic counselling, prognostication, screening for organ involvement, ending the diagnostic odyssey and considering disease modifying interventions"

Supports the surveillance and counselling components of supportive management.

Genetic counselling

Action: Genetic Counseling NCIT:C15240

Autosomal recessive inheritance implies a 25% recurrence risk for future siblings. Carrier testing of parents and prenatal or preimplantation testing are available once the familial variants are known. Counselling is complicated by the wide intrafamilial and interfamilial phenotypic variability, including between patients homozygous for the same allele.

Show evidence (2 references)

PMID:29331171 SUPPORT Human Clinical

"early diagnosis is important for genetic counselling, prognostication, screening for organ involvement"

The cohort authors identify genetic counselling as a primary benefit of molecular diagnosis.

PMID:34990597 SUPPORT Human Clinical

"Of note, patients with the same genetic mutation may not have the same clinical presentation."

Documents the genotype-phenotype unpredictability that constrains prognostic counselling.

🔬

Biochemical Markers

5

Plasma lactate (INCREASED)

Context: The principal screening marker. Eventually elevated in every patient tested (35/35), with an average peak of 13.6 mmol/L and a maximum of 57.8 mmol/L. Persistence of hyperlactataemia despite clinical improvement is common, so lactate is a poor surrogate for treatment response.

Show evidence (1 reference)

PMID:29331171 SUPPORT Human Clinical

"The average recorded peak level of plasma lactate of 13.6 mmol/L (range 3.4 to 57.8 mmol/L)."

Quantifies the magnitude and range of the lactate elevation across the cohort.

Plasma alanine (INCREASED)

Context: Raised in 21/24 (88%) of patients tested, averaging 1346 micromol/L. Alanine accumulates by transamination of the pyruvate that cannot be oxidised, and is a more time-averaged marker of mitochondrial dysfunction than lactate.

Show evidence (1 reference)

PMID:29331171 SUPPORT Human Clinical

"An elevated plasma alanine was documented in 21/24"

Quantifies the frequency of hyperalaninemia across the cohort.

CSF lactate (INCREASED)

Context: Elevated in 5/6 patients in whom lumbar puncture was performed, reflecting the CNS component of the energy deficit. The denominator is very small.

Show evidence (1 reference)

PMID:29331171 SUPPORT Human Clinical

"CSF lactate was elevated in 5/6 cases"

Documents CSF lactate elevation, with the caveat of a six-patient denominator.

Urinary mitochondrial markers (INCREASED)

Context: Every patient whose urine organic acid profile was analysed (14/14) showed some combination of elevated lactate, ketones, TCA-cycle intermediates, tyrosine metabolites, dicarboxylic acids and 3-methylglutaconate. The pattern is non-specific but is a sensitive screening abnormality.

Show evidence (1 reference)

PMID:29331171 SUPPORT Human Clinical

"Markers of mitochondrial dysfunction, including lactate, ketones, TCA (Krebs cycle) metabolites, tyrosine metabolites, dicarboxylic acids and 3-methylglutaconate, were eventually present in the urinary organic acid profile in various patterns in every patient analyzed"

Documents the universal but non-specific urinary organic acid abnormalities.

Respiratory chain enzyme activities in skeletal muscle (DECREASED)

Context: The key confirmatory functional assay. Complex IV was deficient in 28/30 muscle biopsies and 27/30 showed a combined deficiency, most often complex I plus IV (20/30) or complex I plus III plus IV (6/30). Muscle is the diagnostic tissue of choice: fibroblast respiratory chain analysis was normal in 4/10 patients, so a normal fibroblast result does not exclude the diagnosis.

Show evidence (2 references)

PMID:29331171 SUPPORT Human Clinical

"Of the combined deficiencies, complex I and IV deficiency were most commonly seen (20/30 cases) while combined complex I, III and IV deficiency, was present in 6/30 cases."

Quantifies the specific combined respiratory chain patterns observed in patient muscle.

PMID:29331171 SUPPORT Human Clinical

"Importantly the high number of normal results in fibroblasts indicates that normal RCE analysis in this cell type do not exclude the possibility of a MTO1 defect."

Establishes muscle rather than fibroblasts as the appropriate diagnostic tissue.

🔬

Diagnosis

2

Molecular genetic testing

Whole exome sequencing or a targeted mitochondrial-disease gene panel is the most efficient diagnostic route. The clinical and biochemical features are non-specific, and the majority of published cases were diagnosed by sequencing rather than by single-gene testing prompted by a clinical suspicion of MTO1 deficiency.

Show evidence (2 references)

PMID:29331171 SUPPORT Human Clinical

"Molecular confirmation is required and targeted genomic testing may be the most efficient approach."

The cohort authors' explicit diagnostic recommendation.

DOI:10.3390/ijms24032178 SUPPORT Other

"Most of these mutations are sporadic or private, thus it is fundamental that their pathogenicity is confirmed through the use of a model system."

Explains why molecular diagnosis in this disease class often requires functional confirmation - most alleles are private, so classification cannot rely on recurrence alone.

Respiratory chain enzyme analysis in skeletal muscle

A sensitive but non-specific supporting test: respiratory chain enzyme deficiency was present in every case tested in muscle, typically a combined complex I and IV defect. It should be performed on muscle rather than fibroblasts, since fibroblast analysis is normal in a substantial minority of patients. Given its invasiveness, targeted exome sequencing is now generally preferred as the first-line test.

Show evidence (1 reference)

PMID:29331171 SUPPORT Human Clinical

"Respiratory Chain Enzyme (RCE) analysis of muscle is a sensitive (though not specific) test for MTO1 deficiency with enzyme deficiencies in all cases known to date."

Establishes the sensitivity and the specificity limitation of muscle respiratory chain enzyme analysis.

📈

Progression

4

Neonatal presentation

Age: first two days of life

Nearly half of all patients present in the first 48 hours of life, typically with lactic acidosis, respiratory distress/tachypnoea and hypertrophic cardiomyopathy. This is the severe end of the spectrum and carries the worst prognosis.

Show evidence (1 reference)

PMID:29331171 SUPPORT Human Clinical

"15/34 (44%) presented in the first 2 days of life. The average age of presentation was 10.2 months (range: day 1 to 8.0 years)."

Quantifies the neonatal-onset fraction and the overall age-of-presentation range.

Infantile and childhood course

Age: infancy to childhood

Patients surviving the neonatal period accumulate neurological features - global developmental delay, hypotonia, seizures, ataxia - alongside the cardiac and metabolic disease. Optic atrophy typically emerges later than the cardiac and metabolic features. Cardiomyopathy that is absent at presentation may develop over time (present in 44% at presentation but 79% eventually), so serial echocardiography is warranted even in patients with an initially normal heart.

Show evidence (1 reference)

PMID:29331171 SUPPORT Human Clinical

"An extensive review of all known MTO1 deficiency cases revealed the most common features at presentation to be lactic acidosis (LA) (21/34; 62% cases) and hypertrophic cardiomyopathy (15/34; 44% cases). Eventually lactic acidosis and hypertrophic cardiomyopathy are described in 35/35 (100%) and..."

Documents that cardiomyopathy is progressive - rising from 44% at presentation to 79% at follow-up - which is the basis for recommending serial cardiac surveillance.

Mortality

Age: week 1 to 23 years

About a third of reported patients had died at the time of the cohort review, at an average age of 2.67 years. Earlier presentation predicts worse survival: of those presenting in the first two days of life, roughly half died before age 2. Deaths were skewed toward males (8/17 males versus 4/18 females), an observation the cohort authors could not explain biologically and attributed to possible small-cohort artefact. Death in infancy/childhood is recorded here rather than as a phenotype because the corresponding HPO terms sit outside the Phenotypic abnormality subtree.

Show evidence (2 references)

PMID:29331171 SUPPORT Human Clinical

"At the time of writing 12/35 (34%) patients were deceased with an average age of death of 2.67 years (range: week 1 to 23 years)."

Quantifies mortality and its age distribution across the cohort.

PMID:29331171 SUPPORT Human Clinical

"Of those presenting clinically in the first 2 days of life, 7 patients (47%) passed away before the age of 2 years, suggesting a relationship between earlier presentation and a poorer prognosis."

Establishes early presentation as a prognostic marker for early death.

Long-term survival

Age: adolescence to adulthood

A substantial minority survive into adolescence and adulthood, in some cases with normal scholastic performance. Two adolescent sisters described in detail in the cohort report had never developed cardiomyopathy by ages 12 and 16, and one patient treated from infancy with dichloroacetate and cofactors was alive at 20 years with compensated, stable hypertrophic cardiomyopathy.

Show evidence (2 references)

PMID:29331171 SUPPORT Human Clinical

"A further four cases of MTO1 deficiency without cardiomyopathy at ages 0.66 to 22 years, one published and three unpublished, were identified in our review."

Documents long-term survivors who never developed the cardinal cardiac feature.

PMID:23929671 SUPPORT Human Clinical

"he dramatically improved on a permanent treatment with dichloroacetate (DCA) and cofactors, being now 20 years old with compensated, stable hypertrophic cardiomyopathy."

Documents survival to adulthood with compensated cardiomyopathy in a treated patient.

📊

Prevalence

1

Worldwide

Cases In Literature Ultra Rare

No population prevalence estimate exists and Orphanet records none for ORPHA:314637. The disorder was first described in 2012; the largest systematic review assembled 35 molecularly confirmed patients from 26 unrelated families in 11 countries, and a later review counted 42 published cases. The only defensible occurrence statement is therefore a literature case count in the ultra-rare band. Cases have been reported from Austria, Canada, Croatia, Germany, India, Italy, Pakistan, Spain, Syria, Turkey and the United Kingdom, plus subsequent Chinese reports, so the condition is probably pan-ethnic rather than founder-restricted.

Show evidence (3 references)

PMID:29331171 SUPPORT Human Clinical

"An overview of clinical features of the 35 patients (17 males and 18 females) from 11 different countries (Austria, Canada, Croatia, Germany, India, Italy, Pakistan, Turkey, Spain, Syria and the United Kingdom) is presented in Table 1."

Establishes the total published case count and the pan-ethnic geographic distribution underpinning the ultra-rare classification.

PMID:29331171 SUPPORT Human Clinical

"To date cases have been reported in 11 different countries suggesting that MTO1 deficiency is probably a pan-ethnic condition"

Explicit statement that the disorder is pan-ethnic rather than confined to a founder population.

PMID:34990597 SUPPORT Human Clinical

"we presented the detailed clinical features and genetic analysis of the patient with two variants in MTO1, and reviewed 42 different cases available in publications"

A later review counted 42 published cases, confirming the literature remains in the low tens of patients.

🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from MTO1 Deficiency:

GTPBP3 deficiency (COXPD23)

Overlapping Features GTPBP3 encodes the partner subunit of the same wobble-uridine taurinomethylation enzyme, and its deficiency likewise causes infantile hypertrophic cardiomyopathy with lactic acidosis and encephalopathy. The two are clinically near-indistinguishable and are separated by sequencing, though they differ in their cellular metabolic reprogramming response.

Show evidence (1 reference)

PMID:29348686 SUPPORT In Vitro

"Human proteins MTO1 and GTPBP3 are thought to jointly catalyze the modification of the wobble uridine in mitochondrial tRNAs. Defects in each protein cause infantile hypertrophic cardiomyopathy with lactic acidosis."

States the shared enzyme and the shared clinical presentation that makes GTPBP3 deficiency the closest differential.

TRMU deficiency

Overlapping Features TRMU catalyses 2-thiolation of the same wobble uridine that MTO1 taurinomethylates, so the two disorders are mechanistically adjacent. TRMU deficiency is distinguished clinically by severe infantile hepatopathy or renal failure, neither of which is common in MTO1 deficiency.

Show evidence (1 reference)

PMID:29331171 SUPPORT Human Clinical

"While TRMU mutations may result in severe infantile hepatopathy or renal failure neither hepatopathy nor renal pathology are common features in MTO1 deficiency"

Gives the discriminating organ-involvement pattern between the two mt-tRNA modification disorders.

Other nuclear mitochondrial translation defects

Overlapping Features A wider set of nuclear-gene defects in mitochondrial protein synthesis produce the same infantile hypertrophic-cardiomyopathy-plus-lactic-acidosis picture and cannot be separated clinically: mitoribosomal protein defects (including MRPL44/COXPD16), mitochondrial aminoacyl-tRNA synthetase defects (FARS2, AARS2, RARS2), the formyltransferase MTFMT, and the elongation factors TSFM and TUFM. Because MTO1 deficiency belongs to the same "modopathy"/mitochondrial-gene-expression class and its features are non-specific, distinction rests on sequencing rather than on phenotype.

Show evidence (2 references)

DOI:10.3390/ijms24032178 SUPPORT Other

"In recent years, mutations in genes encoding for mt-RNAs modifying enzymes have been identified as being causative of primary mitochondrial diseases, which have been called modopathies."

Establishes the disease class within which MTO1 deficiency sits and from which it must be distinguished molecularly. Tagged OTHER because the source is a narrative review.

PMID:29331171 SUPPORT Human Clinical

"The features of MTO1 deficiency are non-specific which can make accurate diagnosis difficult, often requiring exome sequencing or gene panel analysis."

Confirms that MTO1 deficiency cannot be separated from its mimics on clinical grounds alone.

{ }

Source YAML

click to show

name: MTO1 Deficiency
creation_date: "2026-08-01T00:00:00Z"
category: Mendelian
description: >-
  MTO1 deficiency (combined oxidative phosphorylation deficiency 10, COXPD10;
  mitochondrial hypertrophic cardiomyopathy with lactic acidosis due to MTO1
  deficiency) is a rare autosomal recessive mitochondrial disease caused by
  biallelic pathogenic variants in MTO1, a nuclear gene encoding the
  mitochondrial tRNA translation optimization 1 protein. Together with its
  partner GTPBP3, MTO1 installs 5-taurinomethyluridine (tau-m5U) at the wobble
  (anticodon first) position of five mitochondrial tRNAs - those for Gln, Glu,
  Lys, Leu(UUR) and Trp - using taurine and 5,10-methylene-tetrahydrofolate as
  metabolic substrates. The modification is required for accurate and efficient
  codon-anticodon pairing during mitochondrial translation, so its loss
  attenuates synthesis of the 13 mtDNA-encoded respiratory chain subunits and
  produces a combined respiratory chain defect, most commonly a combined complex
  I and complex IV deficiency in skeletal muscle. Because the affected tissues
  are those with the highest oxidative demand, the cardinal presentation is
  early-onset hypertrophic cardiomyopathy with lactic acidosis, but the
  phenotype is broader than the disease name implies: global developmental
  delay/intellectual disability is nearly universal, and hypotonia, feeding
  difficulties, failure to thrive, seizures, optic atrophy and ataxia are all
  common. The largest published series (35 molecularly confirmed patients)
  established that cardiomyopathy is not obligatory - several patients reached
  adolescence or adulthood without it - and that no patient carries two
  truncating alleles, implying that complete loss of MTO1 is not viable in
  humans. Outcome ranges from neonatal death to survival into the third decade;
  no evidence-based disease-modifying therapy exists.
disease_term:
  preferred_term: MTO1 deficiency
  term:
    id: MONDO:0013865
    label: mitochondrial hypertrophic cardiomyopathy with lactic acidosis due to MTO1 deficiency
parents:
- Mitochondrial Disease
- Inborn Error of Metabolism
synonyms:
- COXPD10
- combined oxidative phosphorylation deficiency 10
- combined oxidative phosphorylation defect type 10
- MTO1 combined oxidative phosphorylation deficiency
- mitochondrial hypertrophic cardiomyopathy with lactic acidosis due to MTO1 deficiency
- ONCE syndrome
notes: >-
  No GeneReviews chapter exists for MTO1 deficiency. A PubMed search for
  "MTO1 GeneReviews" on 2026-08-01 returned a single record, the "Nuclear
  Gene-Encoded Leigh Syndrome Spectrum Overview" (PMID:26425749), whose cached
  abstract does not mention MTO1; the usual GeneReviews phenotype baseline is
  therefore unavailable. In its place this entry is anchored on the largest
  published cohort, O'Byrne et al. 2018 (PMID:29331171, 35 molecularly confirmed
  patients collected through international collaboration), which supplies
  explicit numerators and denominators for every phenotype frequency asserted
  below. Frequencies are quoted directly from that series and carry the caveat
  the authors themselves record: ascertainment was biased by preselection on
  lactic acidosis and cardiomyopathy, denominators vary between features because
  the source literature was incomplete, and later-onset features may be
  under-reported in patients with short follow-up.

  Naming: this entry is filed under the gene-based clinical name "MTO1
  deficiency" used by the cohort literature rather than the longer MONDO label,
  because the MONDO label ("mitochondrial hypertrophic cardiomyopathy with
  lactic acidosis") describes a presentation the cohort showed is not obligatory.
  "ONCE syndrome" (Optic Neuropathy, Cardiomyopathy and Encephalopathy) is a
  synonym coined for the homozygous p.Arg504Cys presentation and is listed as a
  synonym rather than a separate subtype.

  Deliberately excluded to avoid Named Entity Confusion: MTO1 deficiency is
  mechanistically adjacent to, but distinct from, GTPBP3 deficiency (COXPD23,
  the partner subunit of the same tau-m5U enzyme), TRMU deficiency (the
  2-thiouridylase acting on the same wobble uridine), MRPL44 deficiency
  (COXPD16, a mitoribosome defect with the same
  infantile-HCM-plus-lactic-acidosis presentation) and SLC25A3
  cardiomyopathy-hypotonia-lactic acidosis
  syndrome (a phosphate-carrier defect with an overlapping clinical triad that is
  curated separately in this knowledge base). Literature on those disorders is
  cited here only where it reports MTO1 data directly. Identity was verified
  before curation against MONDO:0013865 (gene MTO1/HGNC:19261, OMIM:614702,
  Orphanet:314637); note that OMIM 614667 is the MTO1 *gene* record, not the
  disease record, an ambiguity that recurs in the literature.

  A claim appearing in the deep-research report - that complete Mto1 knockout in
  mouse reduces mitochondrial translation by more than 80% and causes embryonic
  death around E8 - was NOT included because it could not be verified against
  the abstract of the cited review (DOI:10.1093/jb/mvaa098), which does not
  mention MTO1 or embryonic lethality. The related and verifiable human
  inference (no patient carries two truncating alleles, so complete loss is
  probably non-viable) is curated instead.

  Death in infancy/childhood is curated under `progression` rather than as a
  `phenotypes` entry because the relevant HPO terms sit in the Mortality/Aging
  branch, outside the Phenotypic abnormality subtree the PhenotypeTerm dynamic
  enum draws from.
references:
- reference: PMID:22608499
  title: "Mutations of the mitochondrial-tRNA modifier MTO1 cause hypertrophic cardiomyopathy and lactic acidosis."
- reference: PMID:23929671
  title: "MTO1 mutations are associated with hypertrophic cardiomyopathy and lactic acidosis and cause respiratory chain deficiency in humans and yeast."
- reference: PMID:29331171
  title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
- reference: PMID:29390138
  title: "Metabolic and chemical regulation of tRNA modification associated with taurine deficiency and human disease."
- reference: PMID:25506927
  title: "MTO1-deficient mouse model mirrors the human phenotype showing complex I defect and cardiomyopathy."
- reference: PMID:33836087
  title: "Ablation of Mto1 in zebrafish exhibited hypertrophic cardiomyopathy manifested by mitochondrion RNA maturation deficiency."
- reference: PMID:27256614
  title: "The homozygous R504C mutation in MTO1 gene is responsible for ONCE syndrome."
- reference: PMID:26061759
  title: "Optic neuropathy, cardiomyopathy, cognitive disability in patients with a homozygous mutation in the nuclear MTO1 and a mitochondrial MT-TF variant."
- reference: PMID:29348686
  title: "Defects in the mitochondrial-tRNA modification enzymes MTO1 and GTPBP3 promote different metabolic reprogramming through a HIF-PPARγ-UCP2-AMPK axis."
- reference: PMID:27854233
  title: "Cysteine Supplementation May be Beneficial in a Subgroup of Mitochondrial Translation Deficiencies."
- reference: PMID:34990597
  title: "Clinical and genetic analysis of combined oxidative phosphorylation defificiency-10 caused by MTO1 mutation."
- reference: DOI:10.3390/ijms24032178
  title: "Modopathies Caused by Mutations in Genes Encoding for Mitochondrial RNA Modifying Enzymes: Molecular Mechanisms and Yeast Disease Models"
classifications:
  harrisons_chapter:
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
  mechanistic_category:
  - classification_value: mitochondrial disease
  icimd_category:
  - classification_value: mtdna_transcript_processing_and_modification
    notes: >-
      MTO1 is a nuclear-encoded enzyme that post-transcriptionally modifies
      mtDNA-encoded tRNAs (tau-m5U at the wobble uridine), so the disorder
      belongs to ICIMD category 10 "Disorders of mitochondrial gene expression",
      subgroup mtDNA transcript processing and modification - not to a
      respiratory-chain subunit, assembly-factor, or mitoribosome category, even
      though the measured biochemical consequence is a combined respiratory
      chain deficiency. In the recent literature this class of disease is termed
      a mitochondrial RNA "modopathy".
inheritance:
- name: Autosomal recessive
  description: >-
    Disease requires biallelic (homozygous or compound heterozygous) pathogenic
    MTO1 variants. In the 35-patient cohort, 17 patients were homozygous and 18
    compound heterozygous; carrier parents were unaffected and 12/35 patients
    were the offspring of consanguineous unions. Notably no patient carried two
    truncating alleles, indicating that residual MTO1 function is required for
    viability.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sanger sequencing confirmed segregation with disease according to the recessive inheritance model, with carrier status in each parent."
    explanation: Segregation analysis in the index family confirms autosomal recessive inheritance with unaffected heterozygous parents.
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the 35 patients, 17 are homozygous and 13 compound heterozygous for missense variants, four are compound heterozygous for a missense and a frameshift variant and one is compound heterozygous for a missense and a predicted splice-site variant"
    explanation: Documents the biallelic genotype in every patient of the largest published series.
  - reference: PMID:22608499
    reference_title: "Mutations of the mitochondrial-tRNA modifier MTO1 cause hypertrophic cardiomyopathy and lactic acidosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A third unrelated individual was homozygous for the latter change."
    explanation: Homozygosity in an unrelated patient, alongside biparental transmission of two different alleles in the index siblings, establishes recessive inheritance.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    No population prevalence estimate exists and Orphanet records none for
    ORPHA:314637. The disorder was first described in 2012; the largest
    systematic review assembled 35 molecularly confirmed patients from 26
    unrelated families in 11 countries, and a later review counted 42 published
    cases. The only defensible occurrence statement is therefore a literature
    case count in the ultra-rare band. Cases have been reported from Austria,
    Canada, Croatia, Germany, India, Italy, Pakistan, Spain, Syria, Turkey and
    the United Kingdom, plus subsequent Chinese reports, so the condition is
    probably pan-ethnic rather than founder-restricted.
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "An overview of clinical features of the 35 patients (17 males and 18 females) from 11 different countries (Austria, Canada, Croatia, Germany, India, Italy, Pakistan, Turkey, Spain, Syria and the United Kingdom) is presented in Table 1."
    explanation: Establishes the total published case count and the pan-ethnic geographic distribution underpinning the ultra-rare classification.
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To date cases have been reported in 11 different countries suggesting that MTO1 deficiency is probably a pan-ethnic condition"
    explanation: Explicit statement that the disorder is pan-ethnic rather than confined to a founder population.
  - reference: PMID:34990597
    reference_title: "Clinical and genetic analysis of combined oxidative phosphorylation defificiency-10 caused by MTO1 mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we presented the detailed clinical features and genetic analysis of the patient with two variants in MTO1, and reviewed 42 different cases available in publications"
    explanation: A later review counted 42 published cases, confirming the literature remains in the low tens of patients.
progression:
- phase: Neonatal presentation
  age_range: first two days of life
  notes: >-
    Nearly half of all patients present in the first 48 hours of life, typically
    with lactic acidosis, respiratory distress/tachypnoea and hypertrophic
    cardiomyopathy. This is the severe end of the spectrum and carries the worst
    prognosis.
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "15/34 (44%) presented in the first 2 days of life. The average age of presentation was 10.2 months (range: day 1 to 8.0 years)."
    explanation: Quantifies the neonatal-onset fraction and the overall age-of-presentation range.
- phase: Infantile and childhood course
  age_range: infancy to childhood
  notes: >-
    Patients surviving the neonatal period accumulate neurological features -
    global developmental delay, hypotonia, seizures, ataxia - alongside the
    cardiac and metabolic disease. Optic atrophy typically emerges later than the
    cardiac and metabolic features. Cardiomyopathy that is absent at presentation
    may develop over time (present in 44% at presentation but 79% eventually),
    so serial echocardiography is warranted even in patients with an initially
    normal heart.
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "An extensive review of all known MTO1 deficiency cases revealed the most common features at presentation to be lactic acidosis (LA) (21/34; 62% cases) and hypertrophic cardiomyopathy (15/34; 44% cases). Eventually lactic acidosis and hypertrophic cardiomyopathy are described in 35/35 (100%) and 27/34 (79%) of patients with MTO1 deficiency, respectively"
    explanation: Documents that cardiomyopathy is progressive - rising from 44% at presentation to 79% at follow-up - which is the basis for recommending serial cardiac surveillance.
- phase: Mortality
  age_range: week 1 to 23 years
  notes: >-
    About a third of reported patients had died at the time of the cohort
    review, at an average age of 2.67 years. Earlier presentation predicts worse
    survival: of those presenting in the first two days of life, roughly half
    died before age 2. Deaths were skewed toward males (8/17 males versus 4/18
    females), an observation the cohort authors could not explain biologically
    and attributed to possible small-cohort artefact. Death in infancy/childhood
    is recorded here rather than as a phenotype because the corresponding HPO
    terms sit outside the Phenotypic abnormality subtree.
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At the time of writing 12/35 (34%) patients were deceased with an average age of death of 2.67 years (range: week 1 to 23 years)."
    explanation: Quantifies mortality and its age distribution across the cohort.
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of those presenting clinically in the first 2 days of life, 7 patients (47%) passed away before the age of 2 years, suggesting a relationship between earlier presentation and a poorer prognosis."
    explanation: Establishes early presentation as a prognostic marker for early death.
- phase: Long-term survival
  age_range: adolescence to adulthood
  notes: >-
    A substantial minority survive into adolescence and adulthood, in some cases
    with normal scholastic performance. Two adolescent sisters described in
    detail in the cohort report had never developed cardiomyopathy by ages 12 and
    16, and one patient treated from infancy with dichloroacetate and cofactors
    was alive at 20 years with compensated, stable hypertrophic cardiomyopathy.
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A further four cases of MTO1 deficiency without cardiomyopathy at ages 0.66 to 22 years, one published and three unpublished, were identified in our review."
    explanation: Documents long-term survivors who never developed the cardinal cardiac feature.
  - reference: PMID:23929671
    reference_title: "MTO1 mutations are associated with hypertrophic cardiomyopathy and lactic acidosis and cause respiratory chain deficiency in humans and yeast."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "he dramatically improved on a permanent treatment with dichloroacetate (DCA) and cofactors, being now 20 years old with compensated, stable hypertrophic cardiomyopathy."
    explanation: Documents survival to adulthood with compensated cardiomyopathy in a treated patient.
pathophysiology:
- name: Loss of MTO1 Wobble Uridine Taurinomethylation of Mitochondrial tRNAs
  biological_scale: MOLECULAR
  description: >-
    MTO1 and its GTPase partner GTPBP3 jointly catalyse installation of
    5-taurinomethyluridine (tau-m5U) at the anticodon first (wobble) position,
    U34, of five mitochondrially encoded tRNAs: those for glutamine, glutamate,
    lysine, leucine(UUR) and tryptophan. The reaction consumes taurine and
    5,10-methylene-tetrahydrofolate as substrates; older literature describes the
    homologous bacterial/yeast product as 5-carboxymethylaminomethyluridine
    (cmnm5U), the glycine-substituted counterpart that appears in human cells
    when taurine is depleted. Biallelic MTO1 missense or truncating variants
    reduce or abolish the enzyme's modifying activity. No reported patient
    carries two truncating alleles, indicating that some residual MTO1 activity
    is required for human viability; this is the molecular origin of the whole
    disease cascade.
  mechanism_confidence: ESTABLISHED
  gene:
    preferred_term: MTO1
    term:
      id: hgnc:19261
      label: MTO1
  biological_processes:
  - preferred_term: mitochondrial tRNA wobble uridine modification
    term:
      id: GO:0070899
      label: mitochondrial tRNA wobble uridine modification
    modifier: DECREASED
  cellular_components:
  - preferred_term: mitochondrial matrix
    term:
      id: GO:0005759
      label: mitochondrial matrix
  chemical_entities:
  - preferred_term: taurine
    term:
      id: CHEBI:15891
      label: taurine
  evidence:
  - reference: PMID:29390138
    reference_title: "Metabolic and chemical regulation of tRNA modification associated with taurine deficiency and human disease."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "we elucidated τm5U biogenesis by confirming that 5,10-methylene-tetrahydrofolate and taurine are metabolic substrates for τm5U formation catalyzed by MTO1 and GTPBP3."
    explanation: Directly establishes that MTO1 (with GTPBP3) catalyses tau-m5U formation and identifies the two metabolic substrates.
  - reference: PMID:29390138
    reference_title: "Metabolic and chemical regulation of tRNA modification associated with taurine deficiency and human disease."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Modified uridine containing taurine, 5-taurinomethyluridine (τm5U), is found at the anticodon first position of mitochondrial (mt-)transfer RNAs (tRNAs)."
    explanation: Locates the modification at the wobble position of mitochondrial tRNAs.
  - reference: PMID:33836087
    reference_title: "Ablation of Mto1 in zebrafish exhibited hypertrophic cardiomyopathy manifested by mitochondrion RNA maturation deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "pathogenic variants in MTO1 for the biosynthesis of τm5U of tRNAGlu, tRNAGln, tRNALys, tRNATrp and tRNALeu(UUR) were associated with hypertrophic cardiomyopathy (HCM)"
    explanation: Enumerates the five mitochondrial tRNA substrates of MTO1 and links their hypomodification to the cardiac phenotype.
  - reference: PMID:23929671
    reference_title: "MTO1 mutations are associated with hypertrophic cardiomyopathy and lactic acidosis and cause respiratory chain deficiency in humans and yeast."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "encodes one of the two subunits of the enzyme that catalyzes the 5-carboxymethylaminomethylation (mnm5s2U34) of the wobble uridine base in the mitochondrial tRNAs specific to Gln, Glu, Lys, Leu(UUR), and possibly Trp"
    explanation: >-
      The earlier (bacterial/yeast-derived) description of the same wobble-U34
      modification chemistry and the same five tRNA substrates. Retained
      alongside the tau-m5U evidence because the two nomenclatures for this
      modification recur across the MTO1 literature.
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "None of the patients have bi-allelic truncating variants (i.e. frameshift) suggesting that complete loss of MTO1 is unlikely to be viable in humans."
    explanation: Establishes that the human disease reflects partial rather than complete loss of MTO1 function.
  downstream:
  - target: Impaired Mitochondrial Translation
    causal_link_type: DIRECT
    description: >-
      Hypomodified wobble uridines destabilise codon-anticodon pairing and
      reduce the accuracy and efficiency of mtDNA-encoded protein synthesis.
- name: Impaired Mitochondrial Translation
  biological_scale: MOLECULAR
  description: >-
    The tau-m5U/cmnm5U wobble modification increases the accuracy and efficiency
    of mtDNA translation by stabilising tRNA structure, ribosome binding and
    correct codon-anticodon pairing. When it is lost, synthesis of the 13
    mtDNA-encoded polypeptides is attenuated. In the mto1 knock-out zebrafish
    the mechanism is broader than decoding alone: the mutant tRNAs show altered
    conformation, increased nuclease sensitivity and globally reduced
    aminoacylation, and MTO1 additionally interacts with the mitochondrial
    poly(A) polymerase MTPAP so that its loss alters polyadenylation of cox1,
    cox3 and nd1 mRNAs. The translation defect was demonstrated directly in a
    recombinant yeast model carrying the patient alleles.
  mechanism_confidence: ESTABLISHED
  biological_processes:
  - preferred_term: mitochondrial translation
    term:
      id: GO:0032543
      label: mitochondrial translation
    modifier: DECREASED
  evidence:
  - reference: PMID:22608499
    reference_title: "Mutations of the mitochondrial-tRNA modifier MTO1 cause hypertrophic cardiomyopathy and lactic acidosis."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In both humans and yeast, MTO1 increases the accuracy and efficiency of mtDNA translation by catalyzing the 5-carboxymethylaminomethylation of the wobble uridine base in three mitochondrial tRNAs (mt-tRNAs)."
    explanation: States the functional role of the modification in translational accuracy and efficiency.
  - reference: PMID:22608499
    reference_title: "Mutations of the mitochondrial-tRNA modifier MTO1 cause hypertrophic cardiomyopathy and lactic acidosis."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Lastly, in vivo mtDNA translation was impaired in the mutant yeast strains."
    explanation: Direct experimental demonstration that patient-equivalent MTO1 alleles impair mtDNA translation.
  - reference: PMID:33836087
    reference_title: "Ablation of Mto1 in zebrafish exhibited hypertrophic cardiomyopathy manifested by mitochondrion RNA maturation deficiency."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Notably, mto1KO zebrafish exhibited the global decreases in the aminoacylation of mitochondrial tRNAs with the taurine modification."
    explanation: Shows in vivo that loss of the taurine modification reduces mitochondrial tRNA aminoacylation, an additional route to translational failure.
  - reference: PMID:33836087
    reference_title: "Ablation of Mto1 in zebrafish exhibited hypertrophic cardiomyopathy manifested by mitochondrion RNA maturation deficiency."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Strikingly, ablated mto1 mediated the expression of MTPAP and caused the altered polyadenylation of cox1, cox3, and nd1 mRNAs."
    explanation: Documents an mRNA-maturation arm of the mechanism beyond tRNA modification, mediated by an MTO1-MTPAP interaction.
  - reference: DOI:10.3390/ijms24032178
    reference_title: "Modopathies Caused by Mutations in Genes Encoding for Mitochondrial RNA Modifying Enzymes: Molecular Mechanisms and Yeast Disease Models"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "resulting in the absence of/decrease in a specific nucleotide modification and thus on the impairment of the efficiency or the accuracy of the mitochondrial protein synthesis"
    explanation: >-
      Places MTO1 deficiency in the broader "modopathy" class and states the
      shared mechanism - loss of a nucleotide modification impairing the
      efficiency or accuracy of mitochondrial protein synthesis. Tagged OTHER
      because the source is a narrative review rather than primary data.
  downstream:
  - target: Combined Respiratory Chain Complex Deficiency
    causal_link_type: DIRECT
    description: >-
      Reduced synthesis of the mtDNA-encoded core subunits leaves complexes I,
      III, IV and V under-assembled; complex II, which is entirely
      nuclear-encoded, is spared.
- name: Combined Respiratory Chain Complex Deficiency
  biological_scale: CELLULAR
  description: >-
    Attenuated mitochondrial translation produces a combined, rather than
    isolated, respiratory chain enzyme deficiency, because the 13 mtDNA-encoded
    proteins are distributed across complexes I (seven subunits), III (one), IV
    (three) and V (two), while complex II is entirely nuclear-encoded and
    unaffected. In patient skeletal muscle the most frequent pattern is a
    combined complex I and complex IV deficiency; complex IV was deficient in
    28/30 muscle biopsies and a combined deficiency was present in 27/30.
    Fibroblasts are an unreliable tissue for this assay - respiratory chain
    enzymes were normal in 4/10 patient fibroblast lines - so a normal fibroblast
    result does not exclude the diagnosis.
  mechanism_confidence: ESTABLISHED
  biological_processes:
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
    modifier: DECREASED
  cellular_components:
  - preferred_term: mitochondrial respiratory chain complex I
    term:
      id: GO:0045271
      label: respiratory chain complex I
    modifier: DECREASED
  - preferred_term: mitochondrial respiratory chain complex IV
    term:
      id: GO:0045277
      label: respiratory chain complex IV
    modifier: DECREASED
  locations:
  - preferred_term: skeletal muscle tissue
    term:
      id: UBERON:0001134
      label: skeletal muscle tissue
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Respiratory chain enzyme (RCE) analysis in muscle was performed in 30 patients. Complex IV was deficient in 28/30 cases and 27/30 cases showed evidence of combined deficiency."
    explanation: Quantifies the combined respiratory chain deficiency in patient muscle across the cohort.
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This may be explained by the destination of the 13 mtDNA encoded proteins; seven are core subunits of complex I, three of complex IV, two of complex V (although this OXPHOS component cannot be easily measured in frozen diagnostic muscle samples) and one of complex III; complex II is entirely nuclear-encoded."
    explanation: Explains mechanistically why a translation defect yields a combined, complex-II-sparing enzyme deficiency.
  - reference: PMID:22608499
    reference_title: "Mutations of the mitochondrial-tRNA modifier MTO1 cause hypertrophic cardiomyopathy and lactic acidosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Accordingly, mutant muscle and fibroblasts showed variably combined reduction in mtDNA-dependent respiratory chain activities."
    explanation: The index report already established the variably combined respiratory chain reduction in patient tissue.
  - reference: PMID:22608499
    reference_title: "Mutations of the mitochondrial-tRNA modifier MTO1 cause hypertrophic cardiomyopathy and lactic acidosis."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Reduced respiration in mutant cells was corrected by expressing a wild-type MTO1 cDNA."
    explanation: Rescue by wild-type MTO1 cDNA proves the respiratory defect is caused by MTO1 loss of function rather than a bystander effect.
  downstream:
  - target: Cellular Energy Deficit and Lactate Overproduction
    causal_link_type: DIRECT
    description: >-
      Impaired electron transport limits ATP output and diverts pyruvate to
      lactate.
  - target: Cardiomyocyte Bioenergetic Failure and Hypertrophic Remodeling
    causal_link_type: DIRECT
    description: >-
      Cardiomyocytes, with the highest oxidative demand of any cell type in the
      body, are the first tissue to decompensate.
  - target: Neuronal and Retinal Ganglion Cell Energy Failure
    causal_link_type: DIRECT
    description: >-
      Neurons and retinal ganglion cells are the second major
      high-oxidative-demand target of the respiratory chain defect.
  - target: Metabolic Reprogramming via the HIF-PPARgamma-UCP2-AMPK Axis
    causal_link_type: DIRECT
    description: >-
      MTO1-deficient cells mount a distinctive compensatory transcriptional and
      metabolic response to the OXPHOS defect.
- name: Cellular Energy Deficit and Lactate Overproduction
  biological_scale: ORGANISM
  description: >-
    With oxidative phosphorylation constrained, cells shift to glycolysis and
    reduce accumulating pyruvate to lactate, producing the lactic acidosis that
    is the single most consistent biochemical feature of the disorder (eventually
    present in 35/35 patients, with peak plasma lactate averaging 13.6 mmol/L and
    reaching 57.8 mmol/L). Pyruvate accumulation also drives transamination to
    alanine, producing the characteristic hyperalaninemia, and a broad panel of
    mitochondrial markers - ketones, TCA-cycle intermediates, tyrosine
    metabolites, dicarboxylic acids and 3-methylglutaconate - appears in urine.
  mechanism_confidence: ESTABLISHED
  biological_processes:
  - preferred_term: lactate biosynthetic process
    term:
      id: GO:0019249
      label: lactate biosynthetic process
    modifier: INCREASED
  chemical_entities:
  - preferred_term: lactate
    term:
      id: CHEBI:24996
      label: lactate
    modifier: INCREASED
  - preferred_term: L-alanine
    term:
      id: CHEBI:16977
      label: L-alanine
    modifier: INCREASED
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "An extensive review of all known MTO1 deficiency cases revealed the most common features at presentation to be lactic acidosis (LA) (21/34; 62% cases) and hypertrophic cardiomyopathy (15/34; 44% cases). Eventually lactic acidosis and hypertrophic cardiomyopathy are described in 35/35 (100%) and 27/34 (79%) of patients with MTO1 deficiency, respectively"
    explanation: Establishes lactic acidosis as the most frequent presenting biochemical feature and as universal in the cohort once measured.
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "An elevated plasma alanine was documented in 21/24"
    explanation: Quantifies hyperalaninemia as the second consistent biochemical consequence of pyruvate accumulation.
- name: Metabolic Reprogramming via the HIF-PPARgamma-UCP2-AMPK Axis
  biological_scale: CELLULAR
  description: >-
    Patient fibroblasts and MTO1-silenced cells show a specific compensatory
    reprogramming: AMPK is inactivated, UCP2 and PPARgamma are downregulated, and
    HIF-1 is activated. Glycolysis and oxidative phosphorylation become uncoupled
    and fatty-acid metabolism is altered, with accumulation of lipid droplets in
    MTO1 fibroblasts. Notably this response is the mirror image of that seen in
    GTPBP3-depleted cells - which activate AMPK, raise UCP2/PPARgamma and
    inactivate HIF-1 - even though the two proteins act on the same modification,
    suggesting one of them has an additional, non-tRNA-modifying role. This node
    is curated as PROVISIONAL because it rests on fibroblast and knockdown data
    from a single group and has not been demonstrated in patient heart or muscle.
  mechanism_confidence: PROVISIONAL
  cell_types:
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  evidence:
  - reference: PMID:29348686
    reference_title: "Defects in the mitochondrial-tRNA modification enzymes MTO1 and GTPBP3 promote different metabolic reprogramming through a HIF-PPARγ-UCP2-AMPK axis."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Using fibroblasts from an MTO1 patient and MTO1 silenced cells, we found that the MTO1 deficiency is associated with a metabolic reprogramming mediated by inactivation of AMPK, down regulation of the uncoupling protein 2 (UCP2) and transcription factor PPARγ, and activation of the hypoxia inducible factor 1 (HIF-1)."
    explanation: Defines the direction of each arm of the reprogramming axis in MTO1-deficient cells.
  - reference: PMID:29348686
    reference_title: "Defects in the mitochondrial-tRNA modification enzymes MTO1 and GTPBP3 promote different metabolic reprogramming through a HIF-PPARγ-UCP2-AMPK axis."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "As a result, glycolysis and oxidative phosphorylation are uncoupled, while fatty acid metabolism is altered, leading to accumulation of lipid droplets in MTO1 fibroblasts."
    explanation: Documents the downstream metabolic consequence, including lipid droplet accumulation.
  - reference: PMID:29348686
    reference_title: "Defects in the mitochondrial-tRNA modification enzymes MTO1 and GTPBP3 promote different metabolic reprogramming through a HIF-PPARγ-UCP2-AMPK axis."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Therefore, the HIF-PPARγ-UCP2-AMPK axis is operating differently in MTO1- and GTPBP3-defective cells, which strongly suggests that one of these proteins has an additional role, besides mitochondrial-tRNA modification."
    explanation: >-
      Supports the claim only partially - the divergence between MTO1 and GTPBP3
      is observed, but which protein carries the extra function, and whether the
      axis operates the same way in heart or muscle, remains unresolved.
- name: Cardiomyocyte Bioenergetic Failure and Hypertrophic Remodeling
  biological_scale: TISSUE
  description: >-
    Cardiomyocytes have an extremely high and continuous ATP requirement, so they
    are the tissue most sensitive to a combined respiratory chain defect;
    infantile hypertrophic cardiomyopathy is a key clinical feature across many
    mitochondrial disorders and is the presenting feature of MTO1 deficiency in
    almost half of patients. In the Mto1 gene-trap mouse the myocardial damage
    was attributed specifically to complex I deficiency and mitochondrial
    dysfunction, and in the mto1 knock-out zebrafish the ablation produced heart
    developmental defects, cardiomyocyte hypertrophy and myocardial fibre
    disarray in the ventricles, recapitulating the human histological picture.
  mechanism_confidence: ESTABLISHED
  cell_types:
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  locations:
  - preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  evidence:
  - reference: PMID:23929671
    reference_title: "MTO1 mutations are associated with hypertrophic cardiomyopathy and lactic acidosis and cause respiratory chain deficiency in humans and yeast."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Cardiomyocytes, with their extremely high request of energy, are one of the major targets of OXPHOS impairment, and infantile hypertrophic cardiomyopathy is a key clinical feature in many mitochondrial disorders."
    explanation: >-
      States the bioenergetic rationale for cardiac vulnerability. Tagged OTHER
      because the sentence is background framing rather than a patient or
      experimental observation.
  - reference: PMID:33836087
    reference_title: "Ablation of Mto1 in zebrafish exhibited hypertrophic cardiomyopathy manifested by mitochondrion RNA maturation deficiency."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These mitochondria dysfunctions caused heart development defects and hypertrophy of cardiomyocytes and myocardial fiber disarray in ventricles."
    explanation: Demonstrates in vivo that Mto1 loss is sufficient to produce cardiomyocyte hypertrophy and myofibre disarray.
  - reference: PMID:33836087
    reference_title: "Ablation of Mto1 in zebrafish exhibited hypertrophic cardiomyopathy manifested by mitochondrion RNA maturation deficiency."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These cardiac defects in the mto1KO zebrafish recapitulated the clinical phenotypes in HCM patients carrying the MTO1 mutation(s)."
    explanation: The authors' explicit statement that the animal cardiac phenotype recapitulates the human one.
  - reference: PMID:25506927
    reference_title: "MTO1-deficient mouse model mirrors the human phenotype showing complex I defect and cardiomyopathy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The detailed morphological and biochemical workup of murine hearts indicated that the myocardial damage was due to complex I deficiency and mitochondrial dysfunction."
    explanation: Attributes the myocardial damage in the mouse model specifically to the complex I defect.
  downstream:
  - target: Cardiac Conduction Instability
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Mitochondrial dysfunction in the conduction system and working myocardium
      predisposes to bradyarrhythmia and pre-excitation, most clearly documented
      in the mouse model.
- name: Cardiac Conduction Instability
  biological_scale: ORGANISM
  description: >-
    Beyond structural hypertrophy, MTO1 deficiency destabilises cardiac rhythm.
    The MTO1-deficient mouse showed bradycardia alongside cardiomyopathy and, of
    direct translational relevance, a marked worsening of arrhythmias during
    induction of and recovery from anaesthesia - prompting the authors to caution
    against anaesthesia-related arrhythmia in patients. In humans, two patients
    in the reference cohort had Wolff-Parkinson-White pre-excitation, one had
    tachycardia, and the two index siblings of the original 2012 report died in
    the first days of life of sudden bradycardia. The peri-anaesthetic risk
    itself is supported only by mouse data and is therefore curated as
    PROVISIONAL with an accompanying HUMAN_MODEL_MISMATCH discussion.
  mechanism_confidence: PROVISIONAL
  locations:
  - preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  evidence:
  - reference: PMID:25506927
    reference_title: "MTO1-deficient mouse model mirrors the human phenotype showing complex I defect and cardiomyopathy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "As in patients, the most prominent signs and symptoms were cardiovascular and included bradycardia and cardiomyopathy. In addition, the mutant mice showed a marked worsening of arrhythmias during induction and reversal of anaesthesia."
    explanation: Documents both baseline bradycardia and the anaesthesia-provoked arrhythmia worsening in the mouse model.
  - reference: PMID:25506927
    reference_title: "MTO1-deficient mouse model mirrors the human phenotype showing complex I defect and cardiomyopathy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "A translational consequence of this mouse model may be to caution against anaesthesia-related cardiac arrhythmias which may be fatal in patients."
    explanation: >-
      The peri-anaesthetic caution is explicitly framed by the authors as a
      hypothesised translational consequence of a mouse finding, not a
      demonstrated human risk, so this supports the claim only partially.
  - reference: PMID:23929671
    reference_title: "MTO1 mutations are associated with hypertrophic cardiomyopathy and lactic acidosis and cause respiratory chain deficiency in humans and yeast."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "who died in their first days of life due to sudden bradycardia"
    explanation: Human evidence that fatal bradyarrhythmia occurs in MTO1 deficiency, in the two index siblings of the original report.
- name: Neuronal and Retinal Ganglion Cell Energy Failure
  biological_scale: CELLULAR
  description: >-
    Neurons and retinal ganglion cells, like cardiomyocytes, are
    high-oxidative-demand, poorly regenerating cell types, and they constitute
    the second major target of the translation defect. Clinically this produces
    the near-universal global developmental delay/intellectual disability, plus
    hypotonia, seizures, ataxia and optic atrophy; imaging shows basal ganglia,
    cerebellar peduncle and corpus callosum abnormalities in most patients
    scanned. Optic neuropathy is prominent enough in some families that the
    acronym ONCE (Optic Neuropathy, Cardiomyopathy and Encephalopathy with lactic
    acidosis and combined oxidative phosphorylation deficiency) was coined for
    the homozygous p.Arg504Cys presentation.
  mechanism_confidence: ESTABLISHED
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: retinal ganglion cell
    term:
      id: CL:0000740
      label: retinal ganglion cell
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cases included lesions of the basal ganglia and cerebellar peduncles and hypoplasia of the corpus callosum"
    explanation: Documents the structural CNS consequences of the energy deficit in the patients imaged.
  - reference: PMID:27256614
    reference_title: "The homozygous R504C mutation in MTO1 gene is responsible for ONCE syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report clinical and biochemical finding from three unrelated patients presenting ONCE (Optic Neuropathy, Cardiomyopathy and Encephalopathy with lactic acidosis and combined oxidative phosphorylation deficiency) syndrome."
    explanation: Establishes the optic-neuropathy-plus-encephalopathy presentation as a recognised MTO1 phenotype.
  - reference: PMID:26061759
    reference_title: "Optic neuropathy, cardiomyopathy, cognitive disability in patients with a homozygous mutation in the nuclear MTO1 and a mitochondrial MT-TF variant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thus, in patients with a moderate clinical presentation due to MTO1 mutations, the presence of an optic atrophy should be considered."
    explanation: Confirms optic atrophy as a recognised feature that should be looked for in milder MTO1 presentations.
phenotypes:
- category: Metabolic
  name: Lactic Acidosis
  description: >-
    Elevated blood lactate with metabolic acidosis is the most consistent feature
    of the disorder. It was the most frequent presenting biochemical abnormality
    (21/34, 62%) and was eventually documented in every patient tested (35/35).
    Peak plasma lactate averaged 13.6 mmol/L with a range of 3.4 to 57.8 mmol/L.
  phenotype_term:
    preferred_term: Lactic acidosis
    term:
      id: HP:0003128
      label: Lactic acidosis
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Eventually lactic acidosis and hypertrophic cardiomyopathy are described in 35/35 (100%) and 27/34 (79%) of patients with MTO1 deficiency, respectively"
    explanation: >-
      Direct quantitative support for both the association and the frequency
      band. VERY_FREQUENT rather than OBLIGATE is used because the denominator
      reflects only patients in whom lactate was measured and the authors flag
      ascertainment bias toward lactic acidosis.
  - reference: PMID:22608499
    reference_title: "Mutations of the mitochondrial-tRNA modifier MTO1 cause hypertrophic cardiomyopathy and lactic acidosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations of the mitochondrial-tRNA modifier MTO1 cause hypertrophic cardiomyopathy and lactic acidosis."
    explanation: The index report names lactic acidosis as one of the two defining features of the disorder.
- category: Cardiovascular
  name: Hypertrophic Cardiomyopathy
  description: >-
    Hypertrophic cardiomyopathy is the classical cardinal feature and the most
    common presenting sign (15/34, 44%), rising to 27/34 (79%) over follow-up.
    It is nonetheless not obligatory: the cohort identified six patients,
    including two adolescent sisters described in detail, who had no
    cardiomyopathy at ages ranging from 8 months to 22 years. One patient
    developed a dilated rather than hypertrophic form, which the authors suggest
    may be a late progression of an earlier hypertrophic phase.
  phenotype_term:
    preferred_term: Hypertrophic cardiomyopathy
    term:
      id: HP:0001639
      label: Hypertrophic cardiomyopathy
  frequency: FREQUENT
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "An extensive review of all known MTO1 deficiency cases revealed the most common features at presentation to be lactic acidosis (LA) (21/34; 62% cases) and hypertrophic cardiomyopathy (15/34; 44% cases). Eventually lactic acidosis and hypertrophic cardiomyopathy are described in 35/35 (100%) and 27/34 (79%) of patients with MTO1 deficiency, respectively"
    explanation: Direct quantitative support; the eventual 27/34 (79%) sits at the top of the FREQUENT (30-79%) band.
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Together, these six cases prove that HCM is not a hallmark clinical feature of this condition; in fact it was only reported as a presenting feature in approximately half of cases"
    explanation: >-
      Qualifies the association: cardiomyopathy is common but not obligatory,
      which is why the frequency is FREQUENT rather than VERY_FREQUENT despite
      the disease name.
- category: Neurologic
  name: Global Developmental Delay and Intellectual Disability
  description: >-
    Global developmental delay or intellectual disability affected 28/29 (97%) of
    patients for whom the information was available - the single most penetrant
    clinical feature after lactic acidosis. Severity ranges from mild to severe;
    one 19-year-old patient had normal scholastic performance. Because most
    patients present neonatally, delay is often not assessable at presentation
    and emerges over follow-up.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "with global developmental delay/intellectual disability present in 28/29 (97%), feeding difficulties in 17/35 (49%), failure to thrive in 12/35 (34%), seizures in 12/35 (34%), optic atrophy in 11/21 (52%) and ataxia in 7/34 (21%)"
    explanation: Direct quantitative support for the 28/29 (97%) frequency, placing it in the VERY_FREQUENT (80-99%) band.
- category: Neurologic
  name: Intellectual Disability
  description: >-
    In patients surviving to school age the developmental delay resolves into a
    persistent intellectual developmental disorder, typically moderate. The two
    sisters described in detail in the cohort report both had moderate
    intellectual disability at ages 12 and 16.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Virtually all of the patients for whom clinical information was available at a later age did show an intellectual developmental disorder and/or other neurologic impairment."
    explanation: >-
      Supports the association in survivors. No frequency band is asserted
      separately from Global Developmental Delay because the cohort reports the
      two features under a combined GDD/ID denominator.
- category: Neurologic
  name: Hypotonia
  description: >-
    Hypotonia was present in 10/35 (29%) at presentation and eventually in 22/35
    (63%). Some patients had dystonia in addition to, or instead of, hypotonia.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  frequency: FREQUENT
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "but it eventually occurred in 22/35"
    explanation: >-
      Direct quantitative support for the frequency band. The quoted clause is
      the eventual-hypotonia count from the sentence "Hypotonia was identified in
      10/35 ... cases at presentation but it eventually occurred in 22/35 ...
      cases"; 22/35 is 63%, in the FREQUENT (30-79%) band. Only the
      bracket-free clause is quoted because the source sentence interleaves
      square-bracketed confidence intervals.
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other commonly occurring clinical features identified were feeding difficulties, FTT, hypotonia and ocular pathology."
    explanation: Supports the disease-phenotype association itself, independently of the frequency band.
- category: Gastrointestinal
  name: Feeding Difficulties
  description: >-
    Feeding difficulties affected 17/35 (49%) of patients and frequently required
    tube feeding as supportive care.
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  frequency: FREQUENT
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "with global developmental delay/intellectual disability present in 28/29 (97%), feeding difficulties in 17/35 (49%), failure to thrive in 12/35 (34%), seizures in 12/35 (34%), optic atrophy in 11/21 (52%) and ataxia in 7/34 (21%)"
    explanation: Direct quantitative support; 17/35 (49%) falls in the FREQUENT (30-79%) band.
- category: Growth
  name: Failure to Thrive
  description: >-
    Failure to thrive was documented in 12/35 (34%) of patients, usually in
    association with feeding difficulties.
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  frequency: FREQUENT
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "with global developmental delay/intellectual disability present in 28/29 (97%), feeding difficulties in 17/35 (49%), failure to thrive in 12/35 (34%), seizures in 12/35 (34%), optic atrophy in 11/21 (52%) and ataxia in 7/34 (21%)"
    explanation: Direct quantitative support; 12/35 (34%) falls at the lower edge of the FREQUENT (30-79%) band.
- category: Neurologic
  name: Seizures
  description: >-
    Seizures were an uncommon presenting symptom (5/35, 14%) but developed over
    time in 12/35 (34%). Seizure types are heterogeneous - febrile, absence,
    generalised and drop attacks are all described - and can be refractory; one
    patient continued to have up to 40 seizures per week on a ketogenic diet plus
    four antiseizure medications, and another presented in status epilepticus.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  frequency: FREQUENT
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "with global developmental delay/intellectual disability present in 28/29 (97%), feeding difficulties in 17/35 (49%), failure to thrive in 12/35 (34%), seizures in 12/35 (34%), optic atrophy in 11/21 (52%) and ataxia in 7/34 (21%)"
    explanation: Direct quantitative support; the eventual 12/35 (34%) falls at the lower edge of the FREQUENT band.
- category: Ophthalmologic
  name: Optic Atrophy
  description: >-
    Optic atrophy occurred in 11/21 (52%) of patients in whom the optic nerve was
    assessed, with thinning of the retinal nerve fibre layer documented in three.
    It is generally a later feature than the cardiac and metabolic disease and
    can be the dominant manifestation in milder, longer-surviving patients (the
    ONCE presentation). Other ocular findings in the cohort were external
    ophthalmoplegia, unilateral ptosis and mild bilateral cataracts, each in a
    single patient.
  phenotype_term:
    preferred_term: Optic atrophy
    term:
      id: HP:0000648
      label: Optic atrophy
  frequency: FREQUENT
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "with global developmental delay/intellectual disability present in 28/29 (97%), feeding difficulties in 17/35 (49%), failure to thrive in 12/35 (34%), seizures in 12/35 (34%), optic atrophy in 11/21 (52%) and ataxia in 7/34 (21%)"
    explanation: Direct quantitative support; 11/21 (52%) falls in the FREQUENT (30-79%) band.
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cases with thinning of the retinal nerve fibre layer documented in three of these cases"
    explanation: Documents structural retinal nerve fibre layer thinning accompanying the optic atrophy.
  - reference: PMID:26061759
    reference_title: "Optic neuropathy, cardiomyopathy, cognitive disability in patients with a homozygous mutation in the nuclear MTO1 and a mitochondrial MT-TF variant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Ophthalmic investigations (slit lamp examination, funduscopy, OCT scan of the optic nerve, ERG and VEP) disclosed mild or no decreased visual acuity, but pale optic disc, loss of temporal optic fibers and decreased VEPs."
    explanation: Characterises the optic neuropathy phenotype in detail, including preserved acuity despite objective optic nerve findings.
- category: Neurologic
  name: Ataxia
  description: >-
    Ataxia was present in 3/34 (9%) at presentation and 7/34 (21%) over
    follow-up, often of myopathic character with dysmetria, intention tremor and
    dysarthria in longer-surviving patients.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "with global developmental delay/intellectual disability present in 28/29 (97%), feeding difficulties in 17/35 (49%), failure to thrive in 12/35 (34%), seizures in 12/35 (34%), optic atrophy in 11/21 (52%) and ataxia in 7/34 (21%)"
    explanation: Direct quantitative support; the eventual 7/34 (21%) falls in the OCCASIONAL (5-29%) band.
- category: Neurologic
  name: Abnormal Basal Ganglia Morphology
  description: >-
    Brain imaging was abnormal in 14/20 (70%) of patients scanned. Reported
    abnormalities include lesions of the basal ganglia and cerebellar peduncles,
    hypoplasia of the corpus callosum, and anomalies of the claustrum, thalami
    and subcortical white matter. In one patient a metabolic crisis produced
    hyperintense T2/FLAIR signal in the cerebral peduncles, basal ganglia and
    cortex that largely resolved within a week.
  phenotype_term:
    preferred_term: Abnormal basal ganglia morphology
    term:
      id: HP:0002134
      label: Abnormal basal ganglia morphology
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cases included lesions of the basal ganglia and cerebellar peduncles and hypoplasia of the corpus callosum"
    explanation: >-
      Supports basal ganglia involvement. No frequency band is asserted for this
      HPO term specifically because the reported 14/20 denominator covers any
      brain MRI abnormality, not basal ganglia lesions alone.
- category: Neurologic
  name: Hypoplasia of the Corpus Callosum
  description: >-
    Corpus callosum hypoplasia was among the structural brain abnormalities seen
    on MRI in this cohort.
  phenotype_term:
    preferred_term: Hypoplasia of the corpus callosum
    term:
      id: HP:0002079
      label: Hypoplasia of the corpus callosum
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cases included lesions of the basal ganglia and cerebellar peduncles and hypoplasia of the corpus callosum"
    explanation: >-
      Names corpus callosum hypoplasia among the documented MRI abnormalities. No
      frequency is asserted because the cohort does not report a separate
      denominator for this finding.
- category: Musculoskeletal
  name: Muscle Weakness
  description: >-
    Generalised or proximal muscle weakness accompanies the hypotonia in many
    patients and, in longer-surviving patients, becomes a dominant complaint
    together with reduced muscle mass and fatigability.
  phenotype_term:
    preferred_term: Muscle weakness
    term:
      id: HP:0001324
      label: Muscle weakness
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most frequent neurologic features of primary mitochondrial disease are muscle weakness with hypotonia, followed by clinical or imaging features of central neurological disease and cognitive impairment/decline"
    explanation: >-
      Provides disease-class context rather than MTO1-specific support, so this
      item is PARTIAL. No frequency band is asserted because the cohort does not
      report a summary denominator for weakness.
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "decreased muscle mass and proximal muscle strength"
    explanation: Directly documents reduced proximal muscle strength in an MTO1-deficient patient.
- category: Cardiovascular
  name: Wolff-Parkinson-White Syndrome
  description: >-
    Ventricular pre-excitation of Wolff-Parkinson-White type was documented in
    two patients in the reference cohort, in addition to the structural
    cardiomyopathy. It is a rare but clinically important finding because it
    identifies patients at risk of tachyarrhythmia.
  phenotype_term:
    preferred_term: Wolff-Parkinson-White syndrome
    term:
      id: HP:0001716
      label: Wolff-Parkinson-White syndrome
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "21FPakistanC0.42 yrLA, HCM, WPW; DD12 yrYYYYNNRNrHCMWPWPericardial effusionNRNR"
    explanation: >-
      Patient 21's Table 1 row directly records WPW; patient 5 also carries the
      WPW annotation in the table's Abnormal Rhythm column. The OCCASIONAL band
      is a count derived from that table (2/35), not a summary statistic reported
      by the authors.
- category: Hepatic
  name: Hepatic Dysfunction
  description: >-
    Liver involvement is infrequent in MTO1 deficiency (3/35, 9%), which
    distinguishes it from TRMU deficiency - a disorder of the 2-thiolation of the
    same wobble uridine - in which severe infantile hepatopathy is characteristic.
  phenotype_term:
    preferred_term: Abnormal liver physiology
    term:
      id: HP:0031865
      label: Abnormal liver physiology
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hepatic dysfunction was infrequent, present in 3/35"
    explanation: Direct quantitative support; 3/35 is 9%, in the OCCASIONAL (5-29%) band.
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "While TRMU mutations may result in severe infantile hepatopathy or renal failure neither hepatopathy nor renal pathology are common features in MTO1 deficiency"
    explanation: Contrasts the low hepatic burden of MTO1 deficiency with the hepatopathy characteristic of the mechanistically adjacent TRMU deficiency.
- category: Metabolic
  name: Hyperalaninemia
  description: >-
    Elevated plasma alanine, the transamination product of accumulating pyruvate,
    was present in 21/24 (88%) of patients tested, averaging 1346 micromol/L
    (range 630-6560). It is one of the two most useful screening biochemical
    markers alongside lactate.
  phenotype_term:
    preferred_term: Hyperalaninemia
    term:
      id: HP:0003348
      label: Hyperalaninemia
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "An elevated plasma alanine was documented in 21/24"
    explanation: Direct quantitative support; 21/24 is 88%, in the VERY_FREQUENT (80-99%) band.
- category: Metabolic
  name: Increased CSF Lactate
  description: >-
    CSF lactate was elevated in 5 of the 6 patients in whom it was measured,
    reflecting the central nervous system component of the bioenergetic deficit.
  phenotype_term:
    preferred_term: Increased CSF lactate
    term:
      id: HP:0002490
      label: Increased CSF lactate
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CSF lactate was elevated in 5/6 cases"
    explanation: >-
      Supports the association. No frequency band is asserted despite the
      nominal 83% because the denominator is only six patients and the
      confidence interval reported by the authors spans three FrequencyEnum
      bands.
- category: Metabolic
  name: Decreased Activity of Mitochondrial Complex IV
  description: >-
    Cytochrome c oxidase (complex IV) deficiency in skeletal muscle was the most
    consistent enzymatic abnormality, present in 28 of 30 patients biopsied. It
    is usually part of a combined deficiency rather than isolated.
  phenotype_term:
    preferred_term: Decreased activity of mitochondrial complex IV
    term:
      id: HP:0008347
      label: Decreased activity of mitochondrial complex IV
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Complex IV was deficient in 28/30 cases and 27/30 cases showed evidence of combined deficiency."
    explanation: Direct quantitative support; 28/30 (93%) falls in the VERY_FREQUENT (80-99%) band among biopsied patients.
- category: Metabolic
  name: Decreased Activity of Mitochondrial Complex I
  description: >-
    Complex I deficiency accompanies the complex IV defect in the most common
    biochemical signature of the disorder, combined complex I plus IV deficiency,
    seen in 20 of 30 patients biopsied.
  phenotype_term:
    preferred_term: Decreased activity of mitochondrial complex I
    term:
      id: HP:0011923
      label: Decreased activity of mitochondrial complex I
  frequency: FREQUENT
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the combined deficiencies, complex I and IV deficiency were most commonly seen (20/30 cases) while combined complex I, III and IV deficiency, was present in 6/30 cases."
    explanation: >-
      Direct quantitative support; complex I deficiency appears in 20/30 (I+IV)
      plus 6/30 (I+III+IV) of biopsied patients, placing it in the FREQUENT
      (30-79%) band.
biochemical:
- name: Plasma lactate
  presence: INCREASED
  context: >-
    The principal screening marker. Eventually elevated in every patient tested
    (35/35), with an average peak of 13.6 mmol/L and a maximum of 57.8 mmol/L.
    Persistence of hyperlactataemia despite clinical improvement is common, so
    lactate is a poor surrogate for treatment response.
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The average recorded peak level of plasma lactate of 13.6 mmol/L (range 3.4 to 57.8 mmol/L)."
    explanation: Quantifies the magnitude and range of the lactate elevation across the cohort.
- name: Plasma alanine
  presence: INCREASED
  context: >-
    Raised in 21/24 (88%) of patients tested, averaging 1346 micromol/L. Alanine
    accumulates by transamination of the pyruvate that cannot be oxidised, and
    is a more time-averaged marker of mitochondrial dysfunction than lactate.
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "An elevated plasma alanine was documented in 21/24"
    explanation: Quantifies the frequency of hyperalaninemia across the cohort.
- name: CSF lactate
  presence: INCREASED
  context: >-
    Elevated in 5/6 patients in whom lumbar puncture was performed, reflecting
    the CNS component of the energy deficit. The denominator is very small.
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CSF lactate was elevated in 5/6 cases"
    explanation: Documents CSF lactate elevation, with the caveat of a six-patient denominator.
- name: Urinary mitochondrial markers
  presence: INCREASED
  context: >-
    Every patient whose urine organic acid profile was analysed (14/14) showed
    some combination of elevated lactate, ketones, TCA-cycle intermediates,
    tyrosine metabolites, dicarboxylic acids and 3-methylglutaconate. The pattern
    is non-specific but is a sensitive screening abnormality.
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Markers of mitochondrial dysfunction, including lactate, ketones, TCA (Krebs cycle) metabolites, tyrosine metabolites, dicarboxylic acids and 3-methylglutaconate, were eventually present in the urinary organic acid profile in various patterns in every patient analyzed"
    explanation: Documents the universal but non-specific urinary organic acid abnormalities.
- name: Respiratory chain enzyme activities in skeletal muscle
  presence: DECREASED
  context: >-
    The key confirmatory functional assay. Complex IV was deficient in 28/30
    muscle biopsies and 27/30 showed a combined deficiency, most often complex I
    plus IV (20/30) or complex I plus III plus IV (6/30). Muscle is the
    diagnostic tissue of choice: fibroblast respiratory chain analysis was normal
    in 4/10 patients, so a normal fibroblast result does not exclude the
    diagnosis.
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the combined deficiencies, complex I and IV deficiency were most commonly seen (20/30 cases) while combined complex I, III and IV deficiency, was present in 6/30 cases."
    explanation: Quantifies the specific combined respiratory chain patterns observed in patient muscle.
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Importantly the high number of normal results in fibroblasts indicates that normal RCE analysis in this cell type do not exclude the possibility of a MTO1 defect."
    explanation: Establishes muscle rather than fibroblasts as the appropriate diagnostic tissue.
genetic:
- name: MTO1
  notes: >-
    MTO1 encodes mitochondrial tRNA translation optimization 1, an
    evolutionarily conserved FAD-containing protein expressed in
    high-energy-demand tissues. Nineteen different pathogenic variants were
    identified across
    the 35-patient reference cohort - 15 missense, 3 frameshift and one
    splice-site - clustered in the FAD-binding domain, insertion domain 2, the
    GidA-specific sequence motif and the central helical domain. Recurrent
    alleles include p.Ala428Thr, p.Thr411Ile and p.Arg464Cys. Because MTO1 is
    a FAD-containing enzyme, riboflavin supplementation was tried as a rational
    therapy but did not improve respiratory chain or fibroblast oxygen
    consumption measurements. Note that transcript choice matters when comparing
    reports: the cohort re-annotated all variants to NM_012123.3 (isoform a)
    because isoforms b and c are also used in the literature.
  gene_term:
    preferred_term: MTO1
    term:
      id: hgnc:19261
      label: MTO1
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  evidence:
  - reference: PMID:22608499
    reference_title: "Mutations of the mitochondrial-tRNA modifier MTO1 cause hypertrophic cardiomyopathy and lactic acidosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we used next-generation exome sequencing to identify mutations in MTO1, which encodes mitochondrial translation optimization 1."
    explanation: Original gene discovery establishing MTO1 as the causal gene.
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the 35 patients from 26 unrelated families, we identified 19 different MTO1 (NM 012123.3; NP 036255) variants (7 published and 12 unpublished): 15 missense, 3 frameshifts and one splice-site"
    explanation: Defines the allelic spectrum across the largest published cohort.
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The missense variants affect the conserved amino acids located in the: FAD-binding domain (n = 1), insertion domain 2 (n = 1), GidA specific sequence motif (n = 5) and central helical domain (n = 8) of the MTO1"
    explanation: Localises the pathogenic missense variants to four functional protein domains.
  - reference: PMID:23929671
    reference_title: "MTO1 mutations are associated with hypertrophic cardiomyopathy and lactic acidosis and cause respiratory chain deficiency in humans and yeast."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Their pathogenic role was experimentally validated in a recombinant yeast model, by assessing oxidative growth, respiratory activity, mitochondrial protein synthesis, and complex IV activity."
    explanation: Functional validation of the pathogenicity of patient MTO1 alleles in a recombinant yeast system.
  - reference: PMID:27256614
    reference_title: "The homozygous R504C mutation in MTO1 gene is responsible for ONCE syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Therefore, our data confirm p.R504C as pathogenic mutation responsible of ONCE syndrome, and p.V557M as a rare polymorphic variant."
    explanation: Establishes p.Arg504Cys as the allele underlying the ONCE (optic neuropathy) presentation and reclassifies p.Val557Met as benign.
- name: MT-TF
  notes: >-
    A homoplasmic m.593T>G variant in the mitochondrially encoded tRNA-Phe gene
    MT-TF was found alongside a homozygous MTO1 variant in one family with optic
    neuropathy, non-progressive cardiomyopathy and cognitive disability. The
    authors proposed that the mitochondrial variant acts synergistically with the
    MTO1 defect to worsen the complex I deficiency and modulate the phenotype.
    This is a single-family observation and is curated as a candidate modifier,
    not as an established second locus.
  gene_term:
    preferred_term: MT-TF
    term:
      id: hgnc:7481
      label: MT-TF
  relationship_type: MODIFIER
  evidence:
  - reference: PMID:26061759
    reference_title: "Optic neuropathy, cardiomyopathy, cognitive disability in patients with a homozygous mutation in the nuclear MTO1 and a mitochondrial MT-TF variant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The association with the mitochondrial mutation m.593T>G could act synergistically to worsen the complex I deficiency and modulate the MTO1-related disease."
    explanation: >-
      Supports the modifier hypothesis only partially - the authors state the
      synergy as a possibility ("could act") in a single family, with no
      functional demonstration of epistasis.
diagnosis:
- name: Molecular genetic testing
  description: >-
    Whole exome sequencing or a targeted mitochondrial-disease gene panel is the
    most efficient diagnostic route. The clinical and biochemical features are
    non-specific, and the majority of published cases were diagnosed by
    sequencing rather than by single-gene testing prompted by a clinical
    suspicion of MTO1 deficiency.
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Molecular confirmation is required and targeted genomic testing may be the most efficient approach."
    explanation: The cohort authors' explicit diagnostic recommendation.
  - reference: DOI:10.3390/ijms24032178
    reference_title: "Modopathies Caused by Mutations in Genes Encoding for Mitochondrial RNA Modifying Enzymes: Molecular Mechanisms and Yeast Disease Models"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Most of these mutations are sporadic or private, thus it is fundamental that their pathogenicity is confirmed through the use of a model system."
    explanation: >-
      Explains why molecular diagnosis in this disease class often requires
      functional confirmation - most alleles are private, so classification
      cannot rely on recurrence alone.
- name: Respiratory chain enzyme analysis in skeletal muscle
  description: >-
    A sensitive but non-specific supporting test: respiratory chain enzyme
    deficiency was present in every case tested in muscle, typically a combined
    complex I and IV defect. It should be performed on muscle rather than
    fibroblasts, since fibroblast analysis is normal in a substantial minority of
    patients. Given its invasiveness, targeted exome sequencing is now generally
    preferred as the first-line test.
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Respiratory Chain Enzyme (RCE) analysis of muscle is a sensitive (though not specific) test for MTO1 deficiency with enzyme deficiencies in all cases known to date."
    explanation: Establishes the sensitivity and the specificity limitation of muscle respiratory chain enzyme analysis.
differential_diagnoses:
- name: GTPBP3 deficiency (COXPD23)
  description: >-
    GTPBP3 encodes the partner subunit of the same wobble-uridine
    taurinomethylation enzyme, and its deficiency likewise causes infantile
    hypertrophic cardiomyopathy with lactic acidosis and encephalopathy. The two
    are clinically near-indistinguishable and are separated by sequencing, though
    they differ in their cellular metabolic reprogramming response.
  evidence:
  - reference: PMID:29348686
    reference_title: "Defects in the mitochondrial-tRNA modification enzymes MTO1 and GTPBP3 promote different metabolic reprogramming through a HIF-PPARγ-UCP2-AMPK axis."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Human proteins MTO1 and GTPBP3 are thought to jointly catalyze the modification of the wobble uridine in mitochondrial tRNAs. Defects in each protein cause infantile hypertrophic cardiomyopathy with lactic acidosis."
    explanation: States the shared enzyme and the shared clinical presentation that makes GTPBP3 deficiency the closest differential.
- name: TRMU deficiency
  description: >-
    TRMU catalyses 2-thiolation of the same wobble uridine that MTO1
    taurinomethylates, so the two disorders are mechanistically adjacent. TRMU
    deficiency is distinguished clinically by severe infantile hepatopathy or
    renal failure, neither of which is common in MTO1 deficiency.
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "While TRMU mutations may result in severe infantile hepatopathy or renal failure neither hepatopathy nor renal pathology are common features in MTO1 deficiency"
    explanation: Gives the discriminating organ-involvement pattern between the two mt-tRNA modification disorders.
- name: Other nuclear mitochondrial translation defects
  description: >-
    A wider set of nuclear-gene defects in mitochondrial protein synthesis
    produce the same infantile hypertrophic-cardiomyopathy-plus-lactic-acidosis
    picture and cannot be separated clinically: mitoribosomal protein defects
    (including MRPL44/COXPD16), mitochondrial aminoacyl-tRNA synthetase defects
    (FARS2, AARS2, RARS2), the formyltransferase MTFMT, and the elongation
    factors TSFM and TUFM. Because MTO1 deficiency belongs to the same
    "modopathy"/mitochondrial-gene-expression class and its features are
    non-specific, distinction rests on sequencing rather than on phenotype.
  evidence:
  - reference: DOI:10.3390/ijms24032178
    reference_title: "Modopathies Caused by Mutations in Genes Encoding for Mitochondrial RNA Modifying Enzymes: Molecular Mechanisms and Yeast Disease Models"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In recent years, mutations in genes encoding for mt-RNAs modifying enzymes have been identified as being causative of primary mitochondrial diseases, which have been called modopathies."
    explanation: >-
      Establishes the disease class within which MTO1 deficiency sits and from
      which it must be distinguished molecularly. Tagged OTHER because the source
      is a narrative review.
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The features of MTO1 deficiency are non-specific which can make accurate diagnosis difficult, often requiring exome sequencing or gene panel analysis."
    explanation: Confirms that MTO1 deficiency cannot be separated from its mimics on clinical grounds alone.
treatments:
- name: Dichloroacetate
  description: >-
    Dichloroacetate (DCA) was given to 8/25 treated patients with the intent of
    lowering lactate. One patient, homozygous for p.Ala428Thr, improved
    dramatically on permanent DCA plus cofactors and was alive at 20 years with
    compensated stable hypertrophic cardiomyopathy and normal scholastic
    performance. The cohort authors caution that DCA is expected to improve
    lactic acidosis without a clear effect on seizures or neurological outcome,
    and that the concurrent cardiac improvement in that patient may have been
    natural disease course rather than drug effect. This is uncontrolled
    single-patient evidence.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: dichloroacetate
      term:
        id: CHEBI:28240
        label: dichloroacetate
  target_mechanisms:
  - target: Cellular Energy Deficit and Lactate Overproduction
    treatment_effect: INHIBITS
    description: >-
      DCA is used to reduce circulating lactate; it does not address the
      underlying translation defect.
  evidence:
  - reference: PMID:23929671
    reference_title: "MTO1 mutations are associated with hypertrophic cardiomyopathy and lactic acidosis and cause respiratory chain deficiency in humans and yeast."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the clinical outcome was highly variable in patients with the same mutation and seemed also to depend on timely start of pharmacological treatment, centered on the control of lactic acidosis by dichloroacetate."
    explanation: >-
      Supports a possible benefit of early DCA, but only as an inference from
      variable outcomes in a handful of patients with the same genotype, not from
      a controlled comparison.
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Whether or not DCA had a direct positive effect on HCM in patient no. 16 is uncertain and the improvement may have been part of the natural disease course in this case."
    explanation: >-
      The cohort authors explicitly qualify the single reported DCA success,
      which is why this treatment is curated with PARTIAL evidence.
- name: Ketogenic diet
  description: >-
    Trialled in 5/22 patients. Three were deemed unresponsive; one showed clear
    clinical improvement (normalised lactate, learned to walk, resolution of mild
    cardiomyopathy) and one had initially better seizure control that later
    deteriorated. The rationale is strengthened by amelioration of the
    oxidative-phosphorylation defect on a ketogenic diet in MTO1 knockout mice.
    The cohort authors conclude the data are insufficient to draw conclusions but
    that it may be worth cautiously considering in MTO1-deficient patients with
    seizures.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Dietary Intervention
    term:
      id: NCIT:C15447
      label: Dietary Intervention
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A ketogenic diet may have exerted a favourable effect on seizures in 2/5 patients."
    explanation: Documents a possible but inconsistent anticonvulsant benefit in a handful of patients.
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thus the current data are insufficient to draw conclusions about the effectiveness of the ketogenic diet"
    explanation: The cohort authors' own assessment of the evidence base, recorded here so the treatment is not overstated.
- name: Mitochondrial cofactor cocktail
  description: >-
    Various combinations of L-carnitine (14/25), coenzyme Q10 (17/25), riboflavin
    (11/25), vitamin C (6/25), thiamine (5/25) and vitamin E (4/25) were given
    according to local practice. None had an appreciable effect. Riboflavin in
    particular was a rational candidate because MTO1 is a FAD-containing enzyme,
    but it did not improve respiratory chain or fibroblast oxygen consumption
    measurements. Curated here to document that this widely used empirical
    regimen has not shown benefit in this disorder.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Nutritional Support
    term:
      id: NCIT:C15433
      label: Nutritional Support
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "documented objective improvement was rare"
    explanation: >-
      Refutes benefit from the empirical mitochondrial cocktail across the
      cohort; the same paragraph records that L-carnitine, coenzyme Q10, vitamin
      C, vitamin E, riboflavin and thiamine "had no appreciable effect".
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "As MTO1 is a FAD moiety-containing enzyme, riboflavin supplementation was investigated as a possible treatment without observed success in either respiratory chain or fibroblast oxygen consumption analyses"
    explanation: Specifically refutes the mechanistically motivated riboflavin hypothesis.
- name: N-acetylcysteine
  description: >-
    An investigational, cell-culture-only lead. N-acetylcysteine (but not
    L-cysteine) had a beneficial effect on mitochondrial translation in MTO1- and
    TRMU-deficient patient fibroblasts. The rationale is that cysteine supplies
    the sulfur for the 2-thiomodification that is coupled to the wobble-uridine
    modification MTO1 installs. No human trial in MTO1 deficiency has been
    reported.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: N-acetyl-L-cysteine
      term:
        id: CHEBI:28939
        label: N-acetyl-L-cysteine
  target_mechanisms:
  - target: Impaired Mitochondrial Translation
    treatment_effect: RESTORES
    description: >-
      NAC supplementation partially rescued the mitochondrial translation defect
      in MTO1-deficient fibroblasts in vitro.
  evidence:
  - reference: PMID:27854233
    reference_title: "Cysteine Supplementation May be Beneficial in a Subgroup of Mitochondrial Translation Deficiencies."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In contrast, N-acetyl-cysteine had a beneficial effect on mitochondrial translation in TRMU and MTO1 deficient fibroblasts."
    explanation: The single direct experimental result supporting NAC in MTO1 deficiency; it is fibroblast data only.
  - reference: PMID:27854233
    reference_title: "Cysteine Supplementation May be Beneficial in a Subgroup of Mitochondrial Translation Deficiencies."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Further studies are needed to explore the full potential of cysteine supplementation as a treatment for patients with mitochondrial disease."
    explanation: The authors' own statement that the finding is not yet translatable to patient care.
- name: Supportive and multidisciplinary care
  description: >-
    In the absence of disease-modifying therapy, management is supportive:
    inotropes and heart failure management for cardiomyopathy, serial
    echocardiography (cardiomyopathy develops over time in patients who do not
    have it at presentation), tube feeding for feeding difficulties and failure
    to thrive, antiseizure medication, ophthalmological surveillance for optic
    atrophy, and developmental/rehabilitative support. Peri-anaesthetic cardiac
    monitoring is prudent given the arrhythmia worsening observed around
    anaesthesia in the mouse model.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although subjective clinical improvement was observed in a small number of patients on therapies such as ketogenic diet and dichloroacetate, no evidence-based effective therapy exists."
    explanation: Establishes that care is necessarily supportive because no disease-modifying therapy has been validated.
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In general, early diagnosis is important for genetic counselling, prognostication, screening for organ involvement, ending the diagnostic odyssey and considering disease modifying interventions"
    explanation: Supports the surveillance and counselling components of supportive management.
- name: Genetic counselling
  description: >-
    Autosomal recessive inheritance implies a 25% recurrence risk for future
    siblings. Carrier testing of parents and prenatal or preimplantation testing
    are available once the familial variants are known. Counselling is
    complicated by the wide intrafamilial and interfamilial phenotypic
    variability, including between patients homozygous for the same allele.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "early diagnosis is important for genetic counselling, prognostication, screening for organ involvement"
    explanation: The cohort authors identify genetic counselling as a primary benefit of molecular diagnosis.
  - reference: PMID:34990597
    reference_title: "Clinical and genetic analysis of combined oxidative phosphorylation defificiency-10 caused by MTO1 mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of note, patients with the same genetic mutation may not have the same clinical presentation."
    explanation: Documents the genotype-phenotype unpredictability that constrains prognostic counselling.
mechanistic_hypotheses:
- hypothesis_group_id: mto1_residual_function_dose
  hypothesis_label: Residual MTO1 activity determines survival and severity
  status: EMERGING
  description: >-
    The observation that no patient in 35 carries two truncating alleles, and
    that the four patients compound heterozygous for p.Ala428Thr plus a
    frameshift had the earliest presentation (mean 0.04 years) and shortest
    survival (mean 0.24 years), suggests a dose-response relationship in which
    residual MTO1 enzymatic activity sets both viability and severity. The
    hypothesis is consistent with the observation that patients homozygous for
    p.Thr411Ile tend to be more severe while those homozygous for p.Arg464Cys
    survive longer, but it is confounded by the wide phenotypic variability among
    patients sharing an identical genotype, which implies substantial
    modification by other factors.
  evidence:
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We observed that the four patients from three unrelated families who are compound heterozygous for the p.(Ala428Thr) variant and a frameshift variant appear to have more severe presentation: earlier than average age of presentation of clinical features at 0.04 years and shorter than average survival time at 0.24 years, further supporting the hypothesis that residual MTO1 protein function is needed for survival."
    explanation: The primary observation motivating the residual-activity dose hypothesis.
  - reference: PMID:23929671
    reference_title: "MTO1 mutations are associated with hypertrophic cardiomyopathy and lactic acidosis and cause respiratory chain deficiency in humans and yeast."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The severity of the yeast respiratory phenotypes partly correlated with the different clinical presentations observed in MTO1 mutant patients, although the clinical outcome was highly variable in patients with the same mutation"
    explanation: >-
      Yeast allele severity partly tracks clinical severity, supporting the
      hypothesis, but the same sentence records the variability among identical
      genotypes that limits it.
discussions:
- discussion_id: mismatch_anaesthesia_arrhythmia_mouse_only
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: >-
    Does the anaesthesia-provoked arrhythmia worsening seen in Mto1-deficient
    mice occur in patients with MTO1 deficiency, and should it change
    peri-operative management?
  attaches_to:
  - pathophysiology#Cardiac Conduction Instability
  rationale: >-
    The Mto1 gene-trap mouse showed a marked worsening of arrhythmias during
    induction of and reversal from anaesthesia, and the authors explicitly framed
    this as a potentially fatal translational risk. No human case series has
    assessed peri-anaesthetic arrhythmia risk in MTO1 deficiency. Human
    conduction abnormalities are documented (two patients with
    Wolff-Parkinson-White, one with tachycardia, and two index siblings who died
    of sudden bradycardia), so a shared susceptibility is plausible, but the
    specific anaesthetic trigger is unverified in humans. The mismatch matters
    because these patients frequently undergo anaesthesia for muscle biopsy,
    gastrostomy and cardiac procedures.
  proposed_experiments:
  - experiment_id: mto1_perianaesthetic_audit
    name: Retrospective multicentre peri-anaesthetic arrhythmia audit
    description: >-
      Retrospective multicentre audit of peri-anaesthetic ECG and haemodynamic
      events in molecularly confirmed MTO1-deficient patients undergoing general
      anaesthesia, compared with age-matched mitochondrial disease controls.
  - experiment_id: mto1_prospective_holter
    name: Prospective peri-anaesthetic Holter monitoring
    description: >-
      Prospective Holter monitoring around planned anaesthesia in a registry
      cohort, to quantify arrhythmia burden before, during and after induction
      and emergence.
  evidence:
  - reference: PMID:25506927
    reference_title: "MTO1-deficient mouse model mirrors the human phenotype showing complex I defect and cardiomyopathy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "A translational consequence of this mouse model may be to caution against anaesthesia-related cardiac arrhythmias which may be fatal in patients."
    explanation: The mouse observation whose human validity is the open question.
- discussion_id: mismatch_neurological_phenotype_absent_in_mouse
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: >-
    Why is the neurological phenotype nearly universal in patients but largely
    absent in the Mto1-deficient mouse?
  attaches_to:
  - pathophysiology#Neuronal and Retinal Ganglion Cell Energy Failure
  rationale: >-
    Global developmental delay or intellectual disability affects 97% of
    MTO1-deficient patients, and structural brain abnormalities are seen in 70%
    of those imaged. Yet neurological examination was largely normal in the
    Mto1-deficient mouse, whose phenotype was dominated by cardiovascular
    disease. The discrepancy limits the mouse as a preclinical model for the
    neurological arm of the disease - which is the arm most in need of therapy in
    long-term survivors - and raises the question of whether it reflects the
    hypomorphic nature of the gene-trap allele, species differences in neuronal
    dependence on tau-m5U-modified tRNAs, or the shorter murine lifespan.
  proposed_experiments:
  - experiment_id: mto1_aged_mouse_neurophenotyping
    name: Deep neurobehavioural phenotyping of aged and allelic-series Mto1 mice
    description: >-
      Deep neurobehavioural and neuropathological phenotyping of aged
      Mto1-deficient mice, and of allelic series recapitulating the severe human
      genotypes (e.g. missense plus null), to test whether a neurological
      phenotype emerges at lower residual activity or later ages.
  - experiment_id: mto1_cross_species_taum5u_occupancy
    name: Cross-species tissue survey of tau-m5U occupancy
    description: >-
      Quantify tau-m5U occupancy tissue-by-tissue in mouse versus human brain,
      heart and muscle to test whether the neuronal requirement for the
      modification differs between species.
  evidence:
  - reference: PMID:25506927
    reference_title: "MTO1-deficient mouse model mirrors the human phenotype showing complex I defect and cardiomyopathy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In contrast, neurological examination was largely normal in Mto1-deficient mice."
    explanation: Documents the absence of the neurological phenotype in the mouse model.
  - reference: PMID:29331171
    reference_title: "The genotypic and phenotypic spectrum of MTO1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "global developmental delay/intellectual disability present in 28/29 (97%)"
    explanation: Documents the near-universal human neurological phenotype that the mouse fails to reproduce.
- discussion_id: gap_genotype_phenotype_variability_modifiers
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    What determines the marked phenotypic variability between patients carrying
    identical MTO1 genotypes, including within families?
  attaches_to:
  - pathophysiology#Loss of MTO1 Wobble Uridine Taurinomethylation of Mitochondrial tRNAs
  rationale: >-
    Patients homozygous for the same MTO1 allele range from neonatal death to
    survival into the third decade with normal scholastic performance, and
    cardiomyopathy - the eponymous feature - is absent in a sixth of patients.
    Candidate modifiers include mtDNA haplogroup or co-occurring mt-tRNA variants
    (one family carried a homoplasmic MT-TF m.593T>G variant proposed to act
    synergistically), taurine availability (taurine is a substrate for the MTO1
    reaction and taurine starvation reduces tau-m5U frequency in cultured cells
    and animal tissues), and timing of metabolic treatment. None has been tested
    systematically. Resolving this is a prerequisite for prognostic counselling
    and for interpreting any future trial.
  proposed_experiments:
  - experiment_id: mto1_registry_mtdna_background
    name: Genotype-stratified registry with mtDNA background analysis
    description: >-
      Genotype-stratified natural history registry with mtDNA haplogroup and
      full mtDNA sequencing, to test whether mitochondrial background predicts
      severity among patients sharing a nuclear MTO1 genotype.
  - experiment_id: mto1_taurine_modifier_test
    name: Taurine availability as a modifier of tau-m5U occupancy
    description: >-
      Measure plasma and tissue taurine and tau-m5U occupancy in patient-derived
      cells across the severity spectrum, and test whether taurine
      supplementation increases tau-m5U occupancy and mitochondrial translation
      in hypomorphic MTO1 patient cells.
  evidence:
  - reference: PMID:34990597
    reference_title: "Clinical and genetic analysis of combined oxidative phosphorylation defificiency-10 caused by MTO1 mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of note, patients with the same genetic mutation may not have the same clinical presentation. Additional MTO1 defificiency cases will help to make genotype-phenotype correlations clearer."
    explanation: States the unexplained genotype-phenotype discordance that defines this gap.
  - reference: PMID:29390138
    reference_title: "Metabolic and chemical regulation of tRNA modification associated with taurine deficiency and human disease."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Taurine starvation resulted in downregulation of τm5U frequency in cultured cells and animal tissues (cat liver and flatfish)."
    explanation: >-
      Establishes taurine availability as a modifiable determinant of tau-m5U
      occupancy, making it a concrete candidate modifier worth testing in
      patients.

📚

References & Deep Research

References

12

PMID:22608499

Mutations of the mitochondrial-tRNA modifier MTO1 cause hypertrophic cardiomyopathy and lactic acidosis.

No top-level findings curated for this source.

PMID:23929671

MTO1 mutations are associated with hypertrophic cardiomyopathy and lactic acidosis and cause respiratory chain deficiency in humans and yeast.

No top-level findings curated for this source.

PMID:29331171

The genotypic and phenotypic spectrum of MTO1 deficiency.

No top-level findings curated for this source.

PMID:29390138

Metabolic and chemical regulation of tRNA modification associated with taurine deficiency and human disease.

No top-level findings curated for this source.

PMID:25506927

MTO1-deficient mouse model mirrors the human phenotype showing complex I defect and cardiomyopathy.

No top-level findings curated for this source.

PMID:33836087

Ablation of Mto1 in zebrafish exhibited hypertrophic cardiomyopathy manifested by mitochondrion RNA maturation deficiency.

No top-level findings curated for this source.

PMID:27256614

The homozygous R504C mutation in MTO1 gene is responsible for ONCE syndrome.

No top-level findings curated for this source.

PMID:26061759

Optic neuropathy, cardiomyopathy, cognitive disability in patients with a homozygous mutation in the nuclear MTO1 and a mitochondrial MT-TF variant.

No top-level findings curated for this source.

PMID:29348686

Defects in the mitochondrial-tRNA modification enzymes MTO1 and GTPBP3 promote different metabolic reprogramming through a HIF-PPARγ-UCP2-AMPK axis.

No top-level findings curated for this source.

PMID:27854233

Cysteine Supplementation May be Beneficial in a Subgroup of Mitochondrial Translation Deficiencies.

No top-level findings curated for this source.

PMID:34990597

Clinical and genetic analysis of combined oxidative phosphorylation defificiency-10 caused by MTO1 mutation.

No top-level findings curated for this source.

DOI:10.3390/ijms24032178

Modopathies Caused by Mutations in Genes Encoding for Mitochondrial RNA Modifying Enzymes: Molecular Mechanisms and Yeast Disease Models

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

MTO1 Deficiency: Comprehensive Disease-Characteristics Report

Edison Scientific Literature 18 citations 2026-08-01T17:13:02.518455

MTO1 Deficiency: Comprehensive Disease-Characteristics Report

Executive summary

MTO1 deficiency is an ultra-rare, autosomal-recessive mitochondrial translation disorder caused by biallelic pathogenic variants in MTO1. It is classically termed combined oxidative phosphorylation deficiency 10 (COXPD10) or mitochondrial hypertrophic cardiomyopathy with lactic acidosis due to MTO1 deficiency. The central defect is impaired modification and maturation of mitochondrial tRNAs, reducing mitochondrial protein synthesis and oxidative-phosphorylation (OXPHOS) capacity. The heart and nervous system are especially vulnerable.

The largest disease-specific synthesis comprised only 35 affected individuals from 26 families, illustrating both the rarity of the disorder and the limited precision of current frequency and prognostic estimates. In that cohort, eventual frequencies included lactic acidosis in 100%, developmental delay/intellectual disability in 97%, hypertrophic cardiomyopathy in 79%, hypotonia in 63%, optic atrophy in 52%, feeding difficulty in 49%, seizures in 34%, and ataxia in 21%. Overall mortality was 34%, concentrated among patients with neonatal presentation and severe genotypes. No curative or disease-modifying therapy, validated biomarker, formal diagnostic criteria, or MTO1-specific interventional clinical trial was identified. Management is multidisciplinary and supportive. (obyrne2018thegenotypicand pages 9-12, obyrne2018thegenotypicand pages 1-5, obyrne2018thegenotypicand pages 12-16)

The following table provides a compact knowledge-base representation; the narrative sections then document each requested domain.

Domain	Key facts	Suggested ontology IDs	Evidence
Identity / identifiers	MTO1 deficiency is a rare Mendelian mitochondrial disease, commonly described as combined oxidative phosphorylation deficiency-10 (COXPD10) and also as mitochondrial hypertrophic cardiomyopathy with lactic acidosis due to MTO1 deficiency; evidence here is aggregated from published case reports/series rather than EHR-only resources.	MONDO:0013865; OMIM for MTO1 deficiency/COXPD10: not confidently verified here; Orphanet/MeSH/ICD: unavailable or not confidently verified here	(OpenTargets Search: combined oxidative phosphorylation deficiency 10-MTO1, obyrne2018thegenotypicand pages 1-5, obyrne2018thegenotypicand pages 5-9)
Genetics / inheritance	Cause: biallelic pathogenic variants in MTO1 (mitochondrial tRNA translation optimization 1), autosomal recessive. Largest compiled cohort: 35 patients from 26 unrelated families, 17 male/18 female, across 11 countries. Variant spectrum in that cohort: 19 pathogenic variants total (15 missense, 3 frameshift, 1 splice-site); no confirmed biallelic truncating genotypes, suggesting complete loss of function may be incompatible with human survival. Consanguinity reported in 34% of cases.	Gene: MTO1; inheritance term: autosomal recessive (ontology ID not asserted here); GO process suggestions: mitochondrial translational elongation/translation GO:0032543 (mitochondrial translation), oxidative phosphorylation GO:0006119	(obyrne2018thegenotypicand pages 9-12, obyrne2018thegenotypicand pages 12-16, obyrne2018thegenotypicand pages 16-18)
Core phenotype frequencies	Frequent clinical features in the 35-patient series: lactic acidosis 100% eventually; hypertrophic cardiomyopathy 79% eventually (44% presenting feature); developmental delay/intellectual disability 97%; hypotonia 63% eventually; feeding difficulties 49%; optic atrophy 52%; seizures 34%; failure to thrive 34%; ataxia 21%.	HP:0003128 lactic acidosis; HP:0001639 hypertrophic cardiomyopathy; HP:0001263 global developmental delay; HP:0001252 hypotonia; HP:0001250 seizures; HP:0000648 optic atrophy; ataxia: HPO ID not confidently asserted here; failure to thrive: HPO ID not confidently asserted here	(obyrne2018thegenotypicand pages 9-12, obyrne2018thegenotypicand pages 1-5, obyrne2018thegenotypicand pages 5-9)
Biochemical signature	Peak plasma lactate averaged 13.6 mmol/L (range 3.4-57.8). Elevated plasma alanine in 88% of tested patients. Muscle respiratory-chain enzymology commonly showed combined deficiencies, especially complex IV deficiency in 28/30 muscle samples (93%); combined complex I+IV deficiency was most common (20/30). Fibroblast testing can be falsely normal.	CHEBI lactate/alanine: not asserted here; GO:0006120 mitochondrial electron transport, NADH to ubiquinone; GO:0006123 mitochondrial electron transport, cytochrome c to oxygen; GO:0006119 oxidative phosphorylation	(obyrne2018thegenotypicand pages 12-16, obyrne2018thegenotypicand pages 18-22)
Mechanism / causal chain	Upstream defect: impaired MTO1-dependent wobble U34 taurine-related modification of specific mt-tRNAs (reported for mt-tRNA(Glu), mt-tRNA(Gln), mt-tRNA(Lys), mt-tRNA(Trp), mt-tRNA(Leu(UUR))). Intermediate effects: abnormal mt-tRNA structure/stability and aminoacylation, impaired mitochondrial transcript maturation/polyadenylation, reduced mitochondrial translation, defective OXPHOS complex assembly/activity. Downstream effects: bioenergetic failure, increased anaerobic glycolysis/lactic acidosis, altered fatty-acid metabolism with lipid droplet accumulation, cardiomyocyte hypertrophy and multisystem disease. Human fibroblasts further support HIF-1 activation with PPARγ/UCP2/AMPK-axis dysregulation.	GO:0032543 mitochondrial translation; GO:0000959 mitochondrial RNA metabolic process; GO:0006119 oxidative phosphorylation; GO:0006635 fatty acid beta-oxidation; GO:0001666 response to hypoxia; GO:0005739 mitochondrion	(zhang2021ablationofmto1 pages 11-12, boutoual2018defectsinthe pages 1-2, boutoual2018defectsinthe pages 2-3, kazuhito2020posttranscriptionalmodificationsin pages 14-15)
Affected anatomy / cells / compartments	Organs/systems: heart, brain/CNS, skeletal muscle, eye/optic nerve; multisystem disease with high-energy tissues preferentially affected. Imaging abnormalities reported in >70% with involvement of claustrum, thalami, white matter, cerebellar peduncles, and corpus callosum. Cell types implicated include cardiomyocytes and fibroblasts; subcellular localization centers on mitochondria/mitochondrial matrix and inner-membrane respiratory-chain machinery.	UBERON heart/brain/skeletal muscle/eye terms: not confidently asserted here; CL: cardiomyocyte and fibroblast IDs not confidently asserted here; GO:0005739 mitochondrion; GO:0005759 mitochondrial matrix; GO:0005743 mitochondrial inner membrane	(obyrne2018thegenotypicand pages 16-18, zhang2021ablationofmto1 pages 5-6)
Diagnosis	Best-confirming test strategy is genomic: WES or comprehensive mitochondrial/nuclear gene sequencing, because phenotype is nonspecific and fibroblast respiratory-chain testing may miss cases. Supportive findings: elevated lactate/alanine, urinary mitochondrial markers, brain MRI abnormalities, and reduced muscle complex I/III/IV activities. Muscle biopsy with respiratory-chain enzyme analysis is more sensitive than fibroblasts but not specific. Differential diagnosis includes other nuclear mitochondrial-translation disorders causing infantile cardiomyopathy/lactic acidosis (for example GTPBP3, TRMU/MTU1, MTFMT, MRPL44, FARS2, RARS2-related disease).	Diagnostic ontology IDs: not asserted here; GO terms as above may support annotation of functional assays	(obyrne2018thegenotypicand pages 16-18, obyrne2018thegenotypicand pages 37-40, obyrne2018thegenotypicand pages 18-22)
Treatment evidence	No evidence-based disease-specific therapy established. Supportive regimens used include L-carnitine, coenzyme Q10, riboflavin, vitamins, dichloroacetate, and antiseizure therapies; most had little or no appreciable objective benefit. Ketogenic diet showed subjective or seizure-related benefit in a minority (2/5 cases in one summary; 1/5 improved in another extract), so evidence remains limited and individualized. Experimental mechanistic suggestions from cell work include PPARγ agonism/AMPK activation and N-acetyl-cysteine, but these are not established clinical therapies for MTO1 deficiency. No disease-specific interventional clinical trial was retrieved in the tool search.	NCIT intervention IDs: not confidently asserted here; diet/drug ontologies not asserted here	(obyrne2018thegenotypicand pages 12-16, obyrne2018thegenotypicand pages 16-18, obyrne2018thegenotypicand pages 18-22, obyrne2018thegenotypicand pages 1-5)
Prognosis / natural history	Onset ranged from day 1 of life to 8 years (average ~10.2 months); 44% presented within first 2 days of life. Mortality in the 35-patient series was 34% overall, mean age at death 2.67 years; early neonatal presentation predicted worse outcome, and patients with one truncating plus one missense allele had particularly severe disease. Cardiomyopathy is common but not obligatory, and a minority survive into adolescence/adulthood, demonstrating variable expressivity.	Natural-history ontology IDs: not asserted here	(obyrne2018thegenotypicand pages 9-12, obyrne2018thegenotypicand pages 16-18, obyrne2018thegenotypicand pages 12-16)
Models	Zebrafish mto1 knockout recapitulates human hypertrophic cardiomyopathy, showing heart-looping defects, cardiomyocyte hypertrophy, myofiber disarray, mitochondrial fragmentation/cristae loss, impaired mt-tRNA maturation, altered mRNA polyadenylation, and reduced OXPHOS activity. Mouse models: partial knockdown yields mild cardiac phenotype with reduced mitochondrial translation/respiration; complete knockout causes >80% loss of mitochondrial translation and embryonic lethality around E8. Yeast models: conserved MTO1 ortholog supports pathogenicity testing and links U34 hypomodification to mitochondrial translation defects. No clearly established naturally occurring veterinary disease was identified here.	NCBI Taxon suggestions: Danio rerio 7955; Mus musculus 10090; Saccharomyces cerevisiae 4932	(zhang2021ablationofmto1 pages 11-12, magistrati2023modopathiescausedby pages 8-9, zhang2021ablationofmto1 pages 5-6, kazuhito2020posttranscriptionalmodificationsin pages 14-15)

Table: This compact table summarizes high-value knowledge-base facts for MTO1 deficiency, including identifiers, genetics, phenotype frequencies, mechanism, diagnosis, treatment evidence, prognosis, and model systems. It also suggests ontology mappings where the identifier is confidently supported and flags unavailable or uncertain IDs rather than inventing them.

1. Disease information

Definition and classification

MTO1 deficiency is a primary nuclear-encoded mitochondrial disease in which defective mitochondrial RNA modification compromises translation of the 13 mtDNA-encoded OXPHOS polypeptides. It is a Mendelian, multisystem, combined respiratory-chain disorder rather than an isolated sarcomeric cardiomyopathy. Clinical expression ranges from fatal neonatal lactic acidosis and hypertrophic cardiomyopathy to later-onset neurodevelopmental, optic-nerve, or predominantly neurologic disease. Cardiomyopathy is common but not obligatory. (obyrne2018thegenotypicand pages 1-5, obyrne2018thegenotypicand pages 18-22)

Identifiers and names

MONDO: MONDO:0013865, “mitochondrial hypertrophic cardiomyopathy with lactic acidosis due to MTO1 deficiency.” Open Targets links this entity to MTO1/ENSG00000135297 and supporting literature including PMIDs 22608499, 23929671, 27604308, 34547275, 34990597, and 39472908. (OpenTargets Search: combined oxidative phosphorylation deficiency 10-MTO1)
Disease OMIM: commonly reported as COXPD10, OMIM #614702; the O’Byrne paper’s extracted text also associates MTO1 deficiency with OMIM #614667, which is likely a gene/disease-record ambiguity. The identifiers should therefore be checked directly against the current OMIM release before database ingestion.
Gene: MTO1, mitochondrial tRNA translation optimization 1; HGNC symbol MTO1; Ensembl ENSG00000135297. (OpenTargets Search: combined oxidative phosphorylation deficiency 10-MTO1)
Synonyms: MTO1-related disorder; MTO1 deficiency; combined oxidative phosphorylation deficiency 10; COXPD10; mitochondrial hypertrophic cardiomyopathy with lactic acidosis due to MTO1 deficiency; MTO1-related mitochondrial translation disorder.
Orphanet, MeSH, ICD-10/ICD-11: a confidently disease-specific code was not recovered. In clinical coding, the condition may fall under broader mitochondrial-metabolism or cardiomyopathy categories, but these should not be treated as equivalent disease identifiers.

The evidence is predominantly aggregated disease-level literature—case reports, retrospective international case series, and laboratory/model studies—not longitudinal EHR-derived population data. The principal cohort included 35 patients from 11 countries. (obyrne2018thegenotypicand pages 9-12, obyrne2018thegenotypicand pages 16-18)

2. Etiology, risk, protective factors, and gene–environment interaction

Causal factor

The established cause is biallelic germline pathogenic or likely pathogenic variation in MTO1, inherited in an autosomal-recessive manner. MTO1 encodes a mitochondrial tRNA-modifying protein required for efficient wobble-uridine decoding and mitochondrial transcript maturation. Loss of sufficient activity leads to mt-tRNA hypomodification, impaired mitochondrial translation, defective OXPHOS, ATP deficiency, and compensatory glycolysis with lactate accumulation. (zhang2021ablationofmto1 pages 11-12, boutoual2018defectsinthe pages 1-2, boutoual2018defectsinthe pages 2-3)

Genetic risk

In the 35-patient cohort, investigators found 19 variants: 15 missense, three frameshift, and one splice-site variant. Genotypes included homozygous and compound-heterozygous combinations. No patient carried two clearly truncating alleles; patients with one truncating and one missense allele tended to have earlier, more severe disease. Complete MTO1 loss is consequently inferred to be developmentally lethal, consistent with complete mouse knockout. (obyrne2018thegenotypicand pages 1-5, obyrne2018thegenotypicand pages 12-16, kazuhito2020posttranscriptionalmodificationsin pages 14-15)

Examples include c.1451G>A (p.Arg484Gln) and c.1273G>A (p.Gly425Arg) in compound heterozygosity, and c.1392C>T (p.Arg464Cys) in a mechanistically studied patient fibroblast line. Variants reported in affected families are germline, not somatic. Exact ClinVar classifications and current gnomAD frequencies must be assessed variant by variant; the retrieved cohort described the alleles as rare and damaging but does not support a single aggregate carrier-frequency estimate. (obyrne2018thegenotypicand pages 9-12, boutoual2018defectsinthe pages 1-2)

Non-genetic risk and protective factors

No toxin, infection, occupation, sex-specific exposure, smoking behavior, diet, or lifestyle factor is established as a primary cause. Because this is a recessive congenital disorder, family history, parental carrier status, and consanguinity are the relevant risk factors. Consanguinity was reported in approximately 34% of the 35 cases. (obyrne2018thegenotypicand pages 9-12)

No validated protective human allele or environmental protective factor has been established. Residual MTO1 function is plausibly protective: survival with missense or hypomorphic alleles, together with the absence of biallelic null human genotypes, supports a functional threshold. This is a genotype–function inference rather than a clinically validated protective-variant association. (obyrne2018thegenotypicand pages 12-16, obyrne2018thegenotypicand pages 16-18)

Illness, fasting, and catabolic stress can worsen mitochondrial energy imbalance in principle, but an MTO1-specific gene–environment interaction has not been quantified. Ketogenic metabolism may benefit selected patients with epilepsy, yet evidence is sparse and adverse effects are possible; it is not an established environmental modifier of MTO1 penetrance. There are no validated modifier genes, GWAS loci, epigenetic modifiers, or protective pharmacogenomic alleles.

3. Phenotypes

The best frequency estimates come from a heterogeneous, retrospectively assembled 35-person cohort and are susceptible to ascertainment, missing-data, and survival biases. (obyrne2018thegenotypicand pages 18-22)

Major clinical and laboratory phenotypes

Lactic acidosis — HP:0003128; laboratory abnormality/clinical sign. Present initially in 62% and eventually in 100%. Peak plasma lactate averaged 13.6 mmol/L, range 3.4–57.8 mmol/L. It may be neonatal, persistent, episodically exacerbated, and life-threatening. (obyrne2018thegenotypicand pages 12-16)
Hypertrophic cardiomyopathy — HP:0001639; clinical/imaging sign. Presenting feature in 44% and eventually present in 79%. Severity ranges from asymptomatic hypertrophy to heart failure and death. It is often early-onset but is not required for diagnosis. (obyrne2018thegenotypicand pages 9-12, obyrne2018thegenotypicand pages 18-22)
Global developmental delay/intellectual disability — HP:0001263/HP:0001249; developmental phenotype. Reported in 97% of evaluable patients. Severity is variable and usually chronic; it substantially affects education, communication, independence, and caregiver burden. (obyrne2018thegenotypicand pages 9-12)
Hypotonia — HP:0001252; neurologic sign. Eventually present in 63%; contributes to delayed motor development, feeding difficulty, and mobility impairment. (obyrne2018thegenotypicand pages 9-12)
Optic atrophy — HP:0000648; ophthalmic sign. Reported in 52%, potentially causing progressive visual impairment and loss of independence. (obyrne2018thegenotypicand pages 1-5)
Feeding difficulty — HP:0011968; symptom/functional manifestation. Reported in 49%, with aspiration and nutritional risks; some children require intensive feeding support. (obyrne2018thegenotypicand pages 9-12)
Seizures — HP:0001250; neurologic sign. Reported in 34%; severity ranges from controllable epilepsy to refractory seizures requiring multiple antiseizure medicines or ketogenic therapy. (obyrne2018thegenotypicand pages 1-5, obyrne2018thegenotypicand pages 9-12)
Failure to thrive — HP:0001508; growth sign. Reported in 34%, generally secondary to feeding problems and high metabolic demands. (obyrne2018thegenotypicand pages 1-5)
Ataxia — HP:0001251; neurologic sign. Reported in 21%, affecting balance, gait, and activities of daily living. (obyrne2018thegenotypicand pages 1-5)
Elevated alanine — HP:0031987 may be considered; laboratory abnormality. Present in 88% of tested cases, consistent with chronic pyruvate/lactate disequilibrium. (obyrne2018thegenotypicand pages 12-16)
Respiratory-chain deficiency — laboratory/pathology phenotype. Complex IV deficiency occurred in 28/30 muscle samples (93%); 27/30 had combined deficiencies, most commonly complexes I and IV together (20/30). (obyrne2018thegenotypicand pages 12-16)

Brain MRI was abnormal in approximately 70% or more of reported cases, with lesions or signal abnormalities involving white matter, thalami, claustra, corpus callosum, cerebellar peduncles, and other structures; lactate may be detected by MR spectroscopy. The pattern is not disease-specific. (obyrne2018thegenotypicand pages 16-18, obyrne2018thegenotypicand pages 12-16)

No MTO1-specific EQ-5D, SF-36, PROMIS, or validated caregiver-burden study was identified. Quality-of-life impact must therefore be inferred from developmental disability, vision loss, epilepsy, feeding dependence, impaired mobility, repeated metabolic/cardiac surveillance, and risk of heart failure.

4. Genetic and molecular information

Gene and variant architecture

MTO1 is a nuclear gene whose protein product is imported into mitochondria. The disease mechanism is predominantly loss of function or severe reduction of function, not gain of function or dominant-negative activity. Pathogenic classes include missense, frameshift, and splice-altering alleles. Germline biallelic inheritance is established; large rearrangements, chromosomal aneuploidies, repeat expansions, and somatic mutations are not characteristic. (obyrne2018thegenotypicand pages 12-16, boutoual2018defectsinthe pages 1-2)

Variant interpretation should follow ACMG/AMP criteria using segregation, rarity, computational evidence, RNA effects for splice variants, and functional complementation or mitochondrial-translation assays. A VUS should not be considered diagnostic without appropriate evidence. Patient fibroblasts may show a subtle phenotype; muscle or engineered yeast/zebrafish assays can improve functional interpretation. (obyrne2018thegenotypicand pages 18-22, magistrati2023modopathiescausedby pages 8-9)

No confirmed MTO1-specific modifier gene or disease-associated methylation signature is established. The reported association with EEF1A1 in Open Targets appears to reflect variant-record or evidence integration and does not establish EEF1A1 as a causal or modifier gene for MTO1 deficiency. (OpenTargets Search: combined oxidative phosphorylation deficiency 10-MTO1)

5. Environmental, lifestyle, and infectious information

No infectious agent, toxin, radiation exposure, pollution source, occupational factor, alcohol exposure, smoking behavior, or exercise pattern is known to cause MTO1 deficiency. Environmental interventions cannot correct the underlying recessive genotype.

Practical mitochondrial care generally seeks to avoid prolonged fasting, dehydration, and untreated fever or infection because catabolic stress can increase energy demand and lactic acidosis; however, this is extrapolated from mitochondrial medicine rather than demonstrated in an MTO1 trial. Diet changes, particularly ketogenic therapy, require specialist supervision because potential seizure benefit must be balanced against hypoglycemia, acidosis, dyslipidemia, growth effects, and cardiometabolic risk.

6. Mechanism and pathophysiology

Causal chain

Upstream genetic trigger: biallelic MTO1 variants reduce functional mitochondrial MTO1 protein.
Primary molecular lesion: deficient modification of wobble uridine 34 in selected mitochondrial tRNAs, particularly mt-tRNA^Glu, mt-tRNA^Gln, mt-tRNA^Lys, mt-tRNA^Trp, and mt-tRNA^Leu(UUR). Suggested annotations include mitochondrial RNA modification and GO:0032543, mitochondrial translation. (zhang2021ablationofmto1 pages 11-12, boutoual2018defectsinthe pages 1-2)
RNA-level consequences: altered tRNA conformation, reduced stability, increased nuclease sensitivity, and decreased aminoacylation. Zebrafish additionally demonstrate altered MTO1–MTPAP-associated mitochondrial mRNA polyadenylation; the ND1 poly(A) tail fell from about 47 to 33 nucleotides after mto1 ablation. (zhang2021ablationofmto1 pages 11-12)
Translation/OXPHOS consequences: impaired synthesis of mtDNA-encoded respiratory-chain subunits, disturbed OXPHOS complex stoichiometry and assembly, and combined complex I/III/IV dysfunction. Complete mouse knockout reduces mitochondrial translation by more than 80% and causes catastrophic respiratory-complex disassembly. Suggested terms: GO:0006119 oxidative phosphorylation, GO:0006120 mitochondrial electron transport, NADH to ubiquinone, and GO:0006123 mitochondrial electron transport, cytochrome c to oxygen. (boutoual2018defectsinthe pages 2-3, kazuhito2020posttranscriptionalmodificationsin pages 14-15)
Metabolic compensation: ATP deficit promotes glycolytic reliance and lactate accumulation. In patient fibroblasts, MTO1 deficiency inactivates AMPK, decreases PPARγ and UCP2, activates HIF-1, disrupts fatty-acid oxidation, and causes lipid-droplet accumulation. This distinguishes MTO1 from the related GTPBP3 defect and suggests functions beyond tRNA modification. (boutoual2018defectsinthe pages 1-2, boutoual2018defectsinthe pages 2-3)
Cell/tissue injury: high-energy postmitotic cells—especially cardiomyocytes, neurons, skeletal myofibers, and optic-nerve cells—cannot meet energetic demands. Mitochondrial fragmentation, cristae loss, altered proteostasis (including increased LONP1), cardiomyocyte hypertrophy, fiber disarray, and neural dysfunction follow. (boutoual2018defectsinthe pages 2-3, zhang2021ablationofmto1 pages 5-6)
Clinical outcome: hypertrophic cardiomyopathy/heart failure, lactic acidosis, developmental impairment, hypotonia, seizures, optic atrophy, and multisystem morbidity.

Suggested ontology annotations

GO biological processes: GO:0032543 mitochondrial translation; GO:0006119 oxidative phosphorylation; GO:0000959 mitochondrial RNA metabolic process; GO:0006635 fatty-acid beta-oxidation; GO:0001666 response to hypoxia.
GO cellular components: GO:0005739 mitochondrion; GO:0005759 mitochondrial matrix; GO:0005743 mitochondrial inner membrane.
Cell types: cardiomyocyte, neuron, skeletal muscle cell, fibroblast; exact CL identifiers should be ontology-release validated before ingestion.
Chemicals: lactate, alanine, ATP, taurine-containing uridine modifications, coenzyme Q10, riboflavin, levocarnitine, and dichloroacetate; CHEBI identifiers should likewise be release validated.

Molecular profiling and advanced technologies

Disease-specific transcriptomic and metabolic evidence is limited. Fibroblast studies define HIF–PPARγ–UCP2–AMPK reprogramming, while zebrafish heart analyses identify RNA-processing, ribonucleoside-biosynthesis, mRNA-catabolism, and mitochondrial-biogenesis changes. No validated single-cell atlas, spatial transcriptomic study, patient-tissue proteomic signature, lipidomic diagnostic classifier, organoid study, or genome-wide CRISPR therapeutic screen was found. (zhang2021ablationofmto1 pages 11-12, boutoual2018defectsinthe pages 1-2)

A 2023 review characterized these disorders as mitochondrial RNA “modopathies” and emphasized that many variants are private, making conserved yeast systems valuable for pathogenicity testing. (Publication: January 2023; DOI: https://doi.org/10.3390/ijms24032178.) (magistrati2023modopathiescausedby pages 8-9)

7. Anatomical structures affected

Organ and tissue levels

Heart: myocardium, especially ventricular cardiomyocytes; hypertrophy, fiber disarray, impaired respiration, and possible heart failure. Suggested UBERON concepts: heart, myocardium, ventricle.
Central nervous system: cerebral white matter, thalamus, claustrum, corpus callosum, cerebellar pathways, and potentially broader neuronal networks.
Eye/visual pathway: optic nerve and retinal ganglion-cell pathway, reflected by optic atrophy.
Skeletal muscle: mitochondrial myopathy, hypotonia, weakness, and combined respiratory-chain deficiency.
Gastrointestinal/nutritional system: feeding dysfunction and poor growth are often secondary functional consequences.

Disease is generally bilateral/systemic rather than consistently unilateral. No characteristic lateralization is reported. The principal subcellular compartments are the mitochondrial matrix, where RNA modification/translation occurs, and the inner mitochondrial membrane, where OXPHOS complexes reside. (obyrne2018thegenotypicand pages 16-18, zhang2021ablationofmto1 pages 5-6)

8. Temporal development and natural history

Onset in the principal cohort ranged from day 1 to 8 years, averaging approximately 10.2 months; 44% presented during the first two days of life. Onset may be acute with neonatal lactic acidosis or cardiopulmonary decompensation, or insidious with developmental delay, hypotonia, visual loss, or seizures. (obyrne2018thegenotypicand pages 9-12)

The disease is chronic and lifelong in survivors, with a highly variable course. Cardiac and neurologic involvement can emerge after the initial presentation, as illustrated by cardiomyopathy increasing from 44% at presentation to 79% eventually and hypotonia becoming evident in 63%. There is no accepted staging system. Neonatal presentation is a critical vulnerability period: approximately half of neonatal presenters died by two years in the cohort analysis. Conversely, some patients without cardiomyopathy survived into their twenties, demonstrating substantial variable expressivity. (obyrne2018thegenotypicand pages 9-12, obyrne2018thegenotypicand pages 16-18, obyrne2018thegenotypicand pages 18-22)

No spontaneous molecular remission is established. Symptomatic improvement—particularly seizure control—does not represent correction of the underlying mitochondrial translation defect.

9. Inheritance and population characteristics

Inheritance is autosomal recessive. For two confirmed carrier parents, each pregnancy conventionally carries a 25% probability of an affected child, 50% probability of an unaffected carrier, and 25% probability of an unaffected non-carrier, assuming no unusual mosaicism or uniparental mechanism.

Penetrance appears high for pathogenic biallelic genotypes, but expressivity is markedly variable. There is no evidence for genetic anticipation. Germline mosaicism has not emerged as a defining feature, though residual recurrence risk after an apparently de novo event should be discussed according to standard genetic-counseling principles.

The 35-person cohort contained 17 males and 18 females, providing no evidence of a major sex-incidence imbalance. Male mortality was higher in that small cohort—47% at a mean 0.96 years versus 22% at a mean 6.1 years in females—but this observation is underpowered and should not be treated as a proven sex modifier. Cases were reported from 11 countries, supporting a pan-ethnic distribution. No robust prevalence, incidence, carrier frequency, founder effect, endemic region, or population-specific sex ratio is known. (obyrne2018thegenotypicand pages 9-12, obyrne2018thegenotypicand pages 16-18)

10. Diagnostics

Clinical and biochemical evaluation

Suspect MTO1 deficiency in an infant or child with otherwise unexplained combinations of hypertrophic cardiomyopathy, lactic acidosis, developmental delay, hypotonia, seizures, optic atrophy, feeding failure, or combined respiratory-chain deficiency.

Recommended evaluation includes:

Plasma lactate, blood gas, pyruvate, lactate:pyruvate ratio, alanine, glucose, liver and renal indices, CK, acylcarnitines, plasma amino acids, and urine organic acids.
ECG, echocardiography, and rhythm monitoring; cardiac MRI when clinically appropriate.
Brain MRI with diffusion and MR spectroscopy; EEG for seizures.
Ophthalmologic examination, visual electrophysiology where indicated, hearing assessment, developmental evaluation, and nutritional/swallow assessment.
Respiratory-chain enzyme analysis and histology if biopsy is clinically justified. Muscle is more informative than fibroblasts, but combined complex I/IV deficiency is supportive rather than specific. Normal fibroblast enzymology does not exclude MTO1 deficiency. (obyrne2018thegenotypicand pages 16-18, obyrne2018thegenotypicand pages 18-22)

Genetic testing strategy

Preferred: trio WES or WGS with nuclear mitochondrial-gene analysis and copy-number/splice-aware calling.
Alternative: a comprehensive mitochondrial cardiomyopathy/mitochondrial translation panel including MTO1.
Single-gene sequencing: appropriate when familial variants are known or the biochemical phenotype is strongly suggestive; deletion/duplication analysis should be included if sequencing is negative.
RNA sequencing: useful for unresolved splice variants or cryptic splicing, preferably in an informative tissue.
Functional studies: mitochondrial translation, oxygen consumption, respiratory-chain assembly, tRNA modification/stability, or complementation may clarify VUSs.

Karyotyping, FISH, repeat-expansion testing, and isolated mtDNA testing do not directly detect ordinary biallelic MTO1 sequence variants. Chromosomal microarray may detect a rare deletion involving MTO1 but is not a sensitive first-line test for this single-gene disorder.

Differential diagnosis

Important mimics include GTPBP3, TRMU, MTFMT, MRPL44, TSFM, TUFM, FARS2, AARS2, and RARS2 disorders; mtDNA tRNA diseases such as MELAS; pyruvate dehydrogenase deficiency; primary complex I/IV assembly disorders; Pompe disease; fatty-acid oxidation defects; Barth syndrome; and sarcomeric or RASopathy-associated hypertrophic cardiomyopathy. Molecular confirmation is essential because the clinical and biochemical findings are nonspecific. (obyrne2018thegenotypicand pages 18-22, obyrne2018thegenotypicand pages 37-40)

No validated clinical scoring criteria, disease-specific newborn screen, or liquid-biopsy assay exists. Cascade testing is appropriate for relatives after familial variants are established.

11. Outcome and prognosis

In the 35-person series, 34% had died, at an average age of 2.67 years. Early neonatal presentation and a truncating-plus-missense genotype were associated with particularly poor outcomes; reported mean survival for the severe frameshift-containing group was approximately 0.24 years. Complete loss of function is likely embryonically lethal. (obyrne2018thegenotypicand pages 9-12, obyrne2018thegenotypicand pages 12-16)

No reliable five- or ten-year survival curve exists. Potential causes of morbidity and death include severe lactic acidosis, progressive cardiomyopathy/heart failure, arrhythmia, neurologic deterioration, refractory epilepsy, aspiration, and nutritional compromise. Survivors may have lifelong cognitive, visual, motor, and feeding disability. Formal disease-specific quality-of-life and disability-adjusted-life-year data are unavailable.

Useful prognostic indicators are age at presentation, cardiac severity and ventricular function, magnitude/persistence of lactic acidosis, neurologic burden, feeding/respiratory dependence, and genotype class. These are cohort-derived associations, not validated prognostic biomarkers or calculators. (obyrne2018thegenotypicand pages 16-18, obyrne2018thegenotypicand pages 12-16)

12. Treatment and current applications

Current clinical implementation

There is no approved MTO1-specific disease-modifying treatment. Care should be coordinated through mitochondrial medicine, metabolic genetics, cardiology, neurology, nutrition, ophthalmology, rehabilitation, and palliative-care services as appropriate.

Cardiac care: guideline-based surveillance and treatment of cardiomyopathy, heart failure, and arrhythmias. Advanced disease may prompt evaluation for mechanical support or transplantation on an individualized basis; MTO1-specific transplant outcomes are unavailable.
Lactic acidosis/metabolic crises: treat precipitating illness, maintain glucose and hydration, monitor acid–base status, and avoid prolonged fasting. Bicarbonate or renal support is reserved for clinically indicated severe acidosis.
Epilepsy: standard antiseizure medications selected with mitochondrial safety in mind; ketogenic therapy may be considered for refractory epilepsy only in an experienced team.
Nutrition/feeding: dietitian support, swallow evaluation, calorie optimization, and enteral feeding when necessary.
Rehabilitation: physical, occupational, speech, vision, and developmental therapies; exercise should be individualized to avoid exhaustion while preventing deconditioning.

Evidence for specific agents

Cohort treatments included coenzyme Q10 in 68%, levocarnitine in 56%, riboflavin in 44%, dichloroacetate in 32%, and ketogenic diet in 23%, alongside vitamins and other “mitochondrial cocktails.” Most produced “no appreciable effect.” Dichloroacetate was associated with improvement of lactic acidosis and cardiomyopathy in one case, but neuropathy and other toxicity concerns preclude assuming general efficacy. Ketogenic therapy showed seizure-related benefit in only a minority—reported as 2/5 in one analysis—and remains low-quality evidence. (obyrne2018thegenotypicand pages 12-16, obyrne2018thegenotypicand pages 16-18, obyrne2018thegenotypicand pages 1-5)

Mechanistic cell work found partial reversal with the PPARγ agonist rosiglitazone or AMPK activator AICAR, while N-acetylcysteine has been proposed to support mitochondrial translation. These are preclinical hypotheses, not recommended MTO1 treatments. (boutoual2018defectsinthe pages 2-3, obyrne2018thegenotypicand pages 18-22)

No MTO1-specific gene replacement, CRISPR therapy, RNA therapy, cell therapy, immunotherapy, or approved targeted therapy is available. The ClinicalTrials.gov search retrieved no relevant disease-specific interventional trial or NCT identifier. NCIt annotations may include supportive-care, anticonvulsant therapy, cardiac monitoring, physical therapy, occupational therapy, and genetic counseling, but term IDs should be validated against the current NCIt release.

13. Prevention

The phenotype cannot presently be prevented after an affected individual inherits two pathogenic alleles. Primary prevention is therefore reproductive:

genetic counseling and parental segregation testing;
cascade carrier testing for adult relatives;
preimplantation genetic testing for monogenic disease;
prenatal diagnosis by chorionic-villus sampling or amniocentesis for known familial variants;
donor gametes or other reproductive options according to family preferences.

Secondary prevention consists of early molecular diagnosis, baseline cardiac and neurologic assessment, and prospective surveillance before overt organ failure. Tertiary prevention includes vaccination and prompt infection treatment, avoidance of prolonged fasting/dehydration, seizure control, nutritional and aspiration management, and guideline-directed cardiomyopathy care. No vaccine, medication prophylaxis, population newborn-screening program, or behavioral intervention prevents the inherited disorder.

14. Other species and naturally occurring disease

No well-established, naturally occurring companion-animal, livestock, or wildlife syndrome caused by biallelic MTO1 variation was identified. Accordingly, there is no demonstrated zoonotic potential or cross-species transmission; the disease is genetic and noninfectious.

The mechanism is strongly evolutionarily conserved. Relevant taxa include Homo sapiens (NCBI Taxon 9606), Mus musculus (10090), Danio rerio (7955), and Saccharomyces cerevisiae (4932). Conserved yeast Mto1 function permits functional testing of human missense alleles, especially when clinical variants are private. (magistrati2023modopathiescausedby pages 8-9)

15. Model organisms and experimental systems

Zebrafish

CRISPR/Cas9 mto1-knockout Danio rerio are viable and reproduce major human cardiac and mitochondrial phenotypes. Mutants show defective heart looping—no-loop morphology in 58% versus 16% of wild-type embryos—cardiomyocyte hypertrophy, myocardial-fiber disarray, mitochondrial fragmentation and cristae loss, impaired tRNA aminoacylation, altered mRNA polyadenylation, reduced mitochondrial translation, and diminished OXPHOS activity. (zhang2021ablationofmto1 pages 11-12, zhang2021ablationofmto1 pages 5-6)

The primary report’s abstract states: “These cardiac defects in the mto1KO zebrafish recapitulated the clinical phenotypes in HCM patients carrying the MTO1 mutation(s).” This is strong mechanistic evidence for cardiac causality, although zebrafish do not reproduce the full human neurodevelopmental course. Publication: April 2021; DOI: https://doi.org/10.1093/nar/gkab228. (zhang2021ablationofmto1 pages 11-12)

Mouse

Partial Mto1 knockdown produces mild cardiac dilation/fibrosis, decreased mitochondrial translation and complex-I assembly, and impaired cardiac mitochondrial respiration. Complete knockout causes >80% reduction in mitochondrial translation, severe respiratory-complex disassembly, increased anaerobic glycolysis, and embryonic death around E8. This supports a dosage threshold and the inferred nonviability of human biallelic null genotypes. The limitation is that complete knockout models embryonic lethality rather than survivable hypomorphic human disease. (kazuhito2020posttranscriptionalmodificationsin pages 14-15)

Yeast and human cellular models

Saccharomyces cerevisiae MTO1-pathway mutants exhibit respiratory growth and mitochondrial-translation defects and can test pathogenicity of humanized alleles. Species-specific mitochondrial genetic-code and respiratory differences limit direct clinical extrapolation. (magistrati2023modopathiescausedby pages 8-9)

Patient fibroblasts and MTO1-silenced cell lines demonstrate substrate-specific tRNA hypomodification, altered angiogenin sensitivity, OXPHOS/proteostasis imbalance, HIF-1 activation, PPARγ/UCP2/AMPK suppression, defective fatty-acid oxidation, and lipid accumulation. Fibroblasts are experimentally tractable but may underrepresent heart, brain, and muscle disease and can yield normal clinical respiratory-chain assays. (boutoual2018defectsinthe pages 1-2, boutoual2018defectsinthe pages 2-3, obyrne2018thegenotypicand pages 16-18)

Recent developments and expert assessment, 2023–2024

Recent literature has mainly refined the conceptual framework rather than delivered an MTO1-specific therapy. The 2023 mitochondrial RNA-modopathy review emphasized conserved model systems for interpreting private variants and linked loss of RNA modification to inefficient or inaccurate mitochondrial translation. Its abstract summarizes the field: “Most of these mutations are sporadic or private, thus it is fundamental that their pathogenicity is confirmed through the use of a model system.” Publication: January 2023; DOI: https://doi.org/10.3390/ijms24032178. (magistrati2023modopathiescausedby pages 8-9)

A 2024 review of defective mitochondrial protein synthesis emphasized that such disorders are commonly multisystemic and preferentially affect high-energy tissues; it highlighted mouse and zebrafish MTO1 knockouts as cardiac-disease models. A parallel 2024 mouse-model review argued that organ-specific models are essential because mitochondrial-translation disorders show marked tissue specificity. These recent authoritative syntheses support integrated genomic, transcriptomic, proteomic, and tissue-functional approaches, but they do not change current MTO1 clinical management.

The principal expert conclusions are therefore:

Genomic diagnosis should be early and broad, usually WES/WGS rather than phenotype-restricted single-gene testing.
Residual MTO1 activity is a major biological determinant; complete loss appears incompatible with mammalian development.
Cardiomyopathy and lactic acidosis are signature features but not obligatory at presentation, so absence of either should not exclude testing.
Muscle functional testing is more sensitive than fibroblast respiratory-chain enzymology, although molecular confirmation remains decisive.
Therapeutic evidence is insufficient for routine disease-targeted pharmacotherapy; cell-based pathway rescue is hypothesis-generating only. (obyrne2018thegenotypicand pages 18-22, kazuhito2020posttranscriptionalmodificationsin pages 14-15, obyrne2018thegenotypicand pages 16-18)

Evidence limitations and knowledge gaps

The evidence base is dominated by one 35-person retrospective synthesis, individual cases, and preclinical models. There are no population-based incidence studies, prospective natural-history registry, validated patient-reported outcome, randomized treatment trial, disease-specific clinical guideline, standardized biomarker, single-cell human tissue atlas, or established gene therapy. Variant frequencies and classifications evolve and should be refreshed directly from ClinVar and gnomAD. Phenotype percentages should not be interpreted as precise population risks because referral and survival biases probably enrich severe pediatric disease.

References

(obyrne2018thegenotypicand pages 9-12): James J. O'Byrne, Maja Tarailo-Graovac, Aisha Ghani, Michael Champion, Charu Deshpande, Ali Dursun, Riza K. Ozgul, Peter Freisinger, Ian Garber, Tobias B. Haack, Rita Horvath, Ivo Barić, Ralf A. Husain, Leo A.J. Kluijtmans, Urania Kotzaeridou, Andrew A. Morris, Colin J. Ross, Saikat Santra, Jan Smeitink, Mark Tarnopolsky, Saskia B. Wortmann, Johannes A. Mayr, Michaela Brunner-Krainz, Holger Prokisch, Wyeth W. Wasserman, Ron A. Wevers, Udo F. Engelke, Richard J. Rodenburg, Teck Wah Ting, Robert McFarland, Robert W. Taylor, Ramona Salvarinova, and Clara D.M. van Karnebeek. The genotypic and phenotypic spectrum of mto1 deficiency. Molecular Genetics and Metabolism, 123:28-42, Jan 2018. URL: https://doi.org/10.1016/j.ymgme.2017.11.003, doi:10.1016/j.ymgme.2017.11.003. This article has 43 citations and is from a peer-reviewed journal.
(obyrne2018thegenotypicand pages 1-5): James J. O'Byrne, Maja Tarailo-Graovac, Aisha Ghani, Michael Champion, Charu Deshpande, Ali Dursun, Riza K. Ozgul, Peter Freisinger, Ian Garber, Tobias B. Haack, Rita Horvath, Ivo Barić, Ralf A. Husain, Leo A.J. Kluijtmans, Urania Kotzaeridou, Andrew A. Morris, Colin J. Ross, Saikat Santra, Jan Smeitink, Mark Tarnopolsky, Saskia B. Wortmann, Johannes A. Mayr, Michaela Brunner-Krainz, Holger Prokisch, Wyeth W. Wasserman, Ron A. Wevers, Udo F. Engelke, Richard J. Rodenburg, Teck Wah Ting, Robert McFarland, Robert W. Taylor, Ramona Salvarinova, and Clara D.M. van Karnebeek. The genotypic and phenotypic spectrum of mto1 deficiency. Molecular Genetics and Metabolism, 123:28-42, Jan 2018. URL: https://doi.org/10.1016/j.ymgme.2017.11.003, doi:10.1016/j.ymgme.2017.11.003. This article has 43 citations and is from a peer-reviewed journal.
(obyrne2018thegenotypicand pages 12-16): James J. O'Byrne, Maja Tarailo-Graovac, Aisha Ghani, Michael Champion, Charu Deshpande, Ali Dursun, Riza K. Ozgul, Peter Freisinger, Ian Garber, Tobias B. Haack, Rita Horvath, Ivo Barić, Ralf A. Husain, Leo A.J. Kluijtmans, Urania Kotzaeridou, Andrew A. Morris, Colin J. Ross, Saikat Santra, Jan Smeitink, Mark Tarnopolsky, Saskia B. Wortmann, Johannes A. Mayr, Michaela Brunner-Krainz, Holger Prokisch, Wyeth W. Wasserman, Ron A. Wevers, Udo F. Engelke, Richard J. Rodenburg, Teck Wah Ting, Robert McFarland, Robert W. Taylor, Ramona Salvarinova, and Clara D.M. van Karnebeek. The genotypic and phenotypic spectrum of mto1 deficiency. Molecular Genetics and Metabolism, 123:28-42, Jan 2018. URL: https://doi.org/10.1016/j.ymgme.2017.11.003, doi:10.1016/j.ymgme.2017.11.003. This article has 43 citations and is from a peer-reviewed journal.
(OpenTargets Search: combined oxidative phosphorylation deficiency 10-MTO1): Open Targets Query (combined oxidative phosphorylation deficiency 10-MTO1, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(obyrne2018thegenotypicand pages 5-9): James J. O'Byrne, Maja Tarailo-Graovac, Aisha Ghani, Michael Champion, Charu Deshpande, Ali Dursun, Riza K. Ozgul, Peter Freisinger, Ian Garber, Tobias B. Haack, Rita Horvath, Ivo Barić, Ralf A. Husain, Leo A.J. Kluijtmans, Urania Kotzaeridou, Andrew A. Morris, Colin J. Ross, Saikat Santra, Jan Smeitink, Mark Tarnopolsky, Saskia B. Wortmann, Johannes A. Mayr, Michaela Brunner-Krainz, Holger Prokisch, Wyeth W. Wasserman, Ron A. Wevers, Udo F. Engelke, Richard J. Rodenburg, Teck Wah Ting, Robert McFarland, Robert W. Taylor, Ramona Salvarinova, and Clara D.M. van Karnebeek. The genotypic and phenotypic spectrum of mto1 deficiency. Molecular Genetics and Metabolism, 123:28-42, Jan 2018. URL: https://doi.org/10.1016/j.ymgme.2017.11.003, doi:10.1016/j.ymgme.2017.11.003. This article has 43 citations and is from a peer-reviewed journal.
(obyrne2018thegenotypicand pages 16-18): James J. O'Byrne, Maja Tarailo-Graovac, Aisha Ghani, Michael Champion, Charu Deshpande, Ali Dursun, Riza K. Ozgul, Peter Freisinger, Ian Garber, Tobias B. Haack, Rita Horvath, Ivo Barić, Ralf A. Husain, Leo A.J. Kluijtmans, Urania Kotzaeridou, Andrew A. Morris, Colin J. Ross, Saikat Santra, Jan Smeitink, Mark Tarnopolsky, Saskia B. Wortmann, Johannes A. Mayr, Michaela Brunner-Krainz, Holger Prokisch, Wyeth W. Wasserman, Ron A. Wevers, Udo F. Engelke, Richard J. Rodenburg, Teck Wah Ting, Robert McFarland, Robert W. Taylor, Ramona Salvarinova, and Clara D.M. van Karnebeek. The genotypic and phenotypic spectrum of mto1 deficiency. Molecular Genetics and Metabolism, 123:28-42, Jan 2018. URL: https://doi.org/10.1016/j.ymgme.2017.11.003, doi:10.1016/j.ymgme.2017.11.003. This article has 43 citations and is from a peer-reviewed journal.
(obyrne2018thegenotypicand pages 18-22): James J. O'Byrne, Maja Tarailo-Graovac, Aisha Ghani, Michael Champion, Charu Deshpande, Ali Dursun, Riza K. Ozgul, Peter Freisinger, Ian Garber, Tobias B. Haack, Rita Horvath, Ivo Barić, Ralf A. Husain, Leo A.J. Kluijtmans, Urania Kotzaeridou, Andrew A. Morris, Colin J. Ross, Saikat Santra, Jan Smeitink, Mark Tarnopolsky, Saskia B. Wortmann, Johannes A. Mayr, Michaela Brunner-Krainz, Holger Prokisch, Wyeth W. Wasserman, Ron A. Wevers, Udo F. Engelke, Richard J. Rodenburg, Teck Wah Ting, Robert McFarland, Robert W. Taylor, Ramona Salvarinova, and Clara D.M. van Karnebeek. The genotypic and phenotypic spectrum of mto1 deficiency. Molecular Genetics and Metabolism, 123:28-42, Jan 2018. URL: https://doi.org/10.1016/j.ymgme.2017.11.003, doi:10.1016/j.ymgme.2017.11.003. This article has 43 citations and is from a peer-reviewed journal.
(zhang2021ablationofmto1 pages 11-12): Qinghai Zhang, Xiao He, Shihao Yao, Tianxiang Lin, Luwen Zhang, Danni Chen, Chao Chen, Qingxian Yang, Feng Li, Yi-Min Zhu, and Min-Xin Guan. Ablation of mto1 in zebrafish exhibited hypertrophic cardiomyopathy manifested by mitochondrion rna maturation deficiency. Nucleic Acids Research, 49:4689-4704, Apr 2021. URL: https://doi.org/10.1093/nar/gkab228, doi:10.1093/nar/gkab228. This article has 28 citations and is from a highest quality peer-reviewed journal.
(boutoual2018defectsinthe pages 1-2): Rachid Boutoual, Salvador Meseguer, Magda Villarroya, Elena Martín-Hernández, Mohammed Errami, Miguel A. Martín, Marta Casado, and M.-Eugenia Armengod. Defects in the mitochondrial-trna modification enzymes mto1 and gtpbp3 promote different metabolic reprogramming through a hif-pparγ-ucp2-ampk axis. Scientific Reports, Jan 2018. URL: https://doi.org/10.1038/s41598-018-19587-5, doi:10.1038/s41598-018-19587-5. This article has 40 citations and is from a peer-reviewed journal.
(boutoual2018defectsinthe pages 2-3): Rachid Boutoual, Salvador Meseguer, Magda Villarroya, Elena Martín-Hernández, Mohammed Errami, Miguel A. Martín, Marta Casado, and M.-Eugenia Armengod. Defects in the mitochondrial-trna modification enzymes mto1 and gtpbp3 promote different metabolic reprogramming through a hif-pparγ-ucp2-ampk axis. Scientific Reports, Jan 2018. URL: https://doi.org/10.1038/s41598-018-19587-5, doi:10.1038/s41598-018-19587-5. This article has 40 citations and is from a peer-reviewed journal.
(kazuhito2020posttranscriptionalmodificationsin pages 14-15): Tomizawa Kazuhito and Fan-Yan Wei. Posttranscriptional modifications in mitochondrial trna and its implication in mitochondrial translation and disease. Journal of biochemistry, 168:435-444, Aug 2020. URL: https://doi.org/10.1093/jb/mvaa098, doi:10.1093/jb/mvaa098. This article has 28 citations and is from a peer-reviewed journal.
(zhang2021ablationofmto1 pages 5-6): Qinghai Zhang, Xiao He, Shihao Yao, Tianxiang Lin, Luwen Zhang, Danni Chen, Chao Chen, Qingxian Yang, Feng Li, Yi-Min Zhu, and Min-Xin Guan. Ablation of mto1 in zebrafish exhibited hypertrophic cardiomyopathy manifested by mitochondrion rna maturation deficiency. Nucleic Acids Research, 49:4689-4704, Apr 2021. URL: https://doi.org/10.1093/nar/gkab228, doi:10.1093/nar/gkab228. This article has 28 citations and is from a highest quality peer-reviewed journal.
(obyrne2018thegenotypicand pages 37-40): James J. O'Byrne, Maja Tarailo-Graovac, Aisha Ghani, Michael Champion, Charu Deshpande, Ali Dursun, Riza K. Ozgul, Peter Freisinger, Ian Garber, Tobias B. Haack, Rita Horvath, Ivo Barić, Ralf A. Husain, Leo A.J. Kluijtmans, Urania Kotzaeridou, Andrew A. Morris, Colin J. Ross, Saikat Santra, Jan Smeitink, Mark Tarnopolsky, Saskia B. Wortmann, Johannes A. Mayr, Michaela Brunner-Krainz, Holger Prokisch, Wyeth W. Wasserman, Ron A. Wevers, Udo F. Engelke, Richard J. Rodenburg, Teck Wah Ting, Robert McFarland, Robert W. Taylor, Ramona Salvarinova, and Clara D.M. van Karnebeek. The genotypic and phenotypic spectrum of mto1 deficiency. Molecular Genetics and Metabolism, 123:28-42, Jan 2018. URL: https://doi.org/10.1016/j.ymgme.2017.11.003, doi:10.1016/j.ymgme.2017.11.003. This article has 43 citations and is from a peer-reviewed journal.
(magistrati2023modopathiescausedby pages 8-9): Martina Magistrati, Alexandru Ionut Gilea, Camilla Ceccatelli Berti, Enrico Baruffini, and Cristina Dallabona. Modopathies caused by mutations in genes encoding for mitochondrial rna modifying enzymes: molecular mechanisms and yeast disease models. International Journal of Molecular Sciences, 24:2178, Jan 2023. URL: https://doi.org/10.3390/ijms24032178, doi:10.3390/ijms24032178. This article has 14 citations.

Artifacts

Edison artifact artifact-00

Ask OpenScientist

OpenScientist Report

Classifications

Inheritance

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Diagnosis

Progression

Prevalence

Differential Diagnoses

Source YAML

References & Deep Research

References

Deep Research

MTO1 Deficiency: Comprehensive Disease-Characteristics Report

Executive summary

1. Disease information

Definition and classification

Identifiers and names

2. Etiology, risk, protective factors, and gene–environment interaction

Causal factor

Genetic risk

Non-genetic risk and protective factors

3. Phenotypes

Major clinical and laboratory phenotypes

4. Genetic and molecular information

Gene and variant architecture

5. Environmental, lifestyle, and infectious information

6. Mechanism and pathophysiology

Causal chain

Suggested ontology annotations

Molecular profiling and advanced technologies

7. Anatomical structures affected

Organ and tissue levels

8. Temporal development and natural history

9. Inheritance and population characteristics

10. Diagnostics

Clinical and biochemical evaluation

Genetic testing strategy

Differential diagnosis

11. Outcome and prognosis

12. Treatment and current applications

Current clinical implementation

Evidence for specific agents

13. Prevention

14. Other species and naturally occurring disease

15. Model organisms and experimental systems

Zebrafish

Mouse

Yeast and human cellular models

Recent developments and expert assessment, 2023–2024

Evidence limitations and knowledge gaps

Artifacts